CA2869169A1 - Methods and compositions using fgf-9 to enhance neovascularization and regeneration - Google Patents
Methods and compositions using fgf-9 to enhance neovascularization and regeneration Download PDFInfo
- Publication number
- CA2869169A1 CA2869169A1 CA2869169A CA2869169A CA2869169A1 CA 2869169 A1 CA2869169 A1 CA 2869169A1 CA 2869169 A CA2869169 A CA 2869169A CA 2869169 A CA2869169 A CA 2869169A CA 2869169 A1 CA2869169 A1 CA 2869169A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- subject
- cells
- stem cells
- apoptosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 265
- 238000000034 method Methods 0.000 title claims abstract description 250
- 206010029113 Neovascularisation Diseases 0.000 title claims abstract description 89
- 230000008929 regeneration Effects 0.000 title description 12
- 238000011069 regeneration method Methods 0.000 title description 12
- 101150112093 FGF9 gene Proteins 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 claims abstract description 244
- 230000002708 enhancing effect Effects 0.000 claims abstract description 108
- 230000002792 vascular Effects 0.000 claims abstract description 92
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 34
- 210000004027 cell Anatomy 0.000 claims description 485
- 102000003957 Fibroblast growth factor 9 Human genes 0.000 claims description 293
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 claims description 293
- 230000000747 cardiac effect Effects 0.000 claims description 130
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 129
- 230000007246 mechanism Effects 0.000 claims description 114
- 239000003636 conditioned culture medium Substances 0.000 claims description 94
- 208000010125 myocardial infarction Diseases 0.000 claims description 89
- 230000014509 gene expression Effects 0.000 claims description 83
- 230000004064 dysfunction Effects 0.000 claims description 80
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 claims description 72
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 claims description 72
- 239000003018 immunosuppressive agent Substances 0.000 claims description 62
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 61
- 230000007423 decrease Effects 0.000 claims description 51
- 210000000130 stem cell Anatomy 0.000 claims description 49
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 42
- 210000004165 myocardium Anatomy 0.000 claims description 41
- 108091028066 Mir-126 Proteins 0.000 claims description 38
- 230000004217 heart function Effects 0.000 claims description 37
- 230000001965 increasing effect Effects 0.000 claims description 34
- 206010012601 diabetes mellitus Diseases 0.000 claims description 33
- 210000002889 endothelial cell Anatomy 0.000 claims description 30
- 230000010410 reperfusion Effects 0.000 claims description 28
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- 101001120097 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit beta Proteins 0.000 claims description 23
- 102100026177 Phosphatidylinositol 3-kinase regulatory subunit beta Human genes 0.000 claims description 23
- 101000881230 Homo sapiens Sprouty-related, EVH1 domain-containing protein 1 Proteins 0.000 claims description 22
- 102100037614 Sprouty-related, EVH1 domain-containing protein 1 Human genes 0.000 claims description 22
- 230000033115 angiogenesis Effects 0.000 claims description 22
- 210000002950 fibroblast Anatomy 0.000 claims description 20
- 210000005003 heart tissue Anatomy 0.000 claims description 20
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 19
- 208000031225 myocardial ischemia Diseases 0.000 claims description 18
- 230000004862 vasculogenesis Effects 0.000 claims description 18
- 206010061216 Infarction Diseases 0.000 claims description 17
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 17
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 17
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 17
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 17
- -1 oct 3/4 Proteins 0.000 claims description 17
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 16
- 230000024245 cell differentiation Effects 0.000 claims description 16
- 208000028831 congenital heart disease Diseases 0.000 claims description 16
- 210000004351 coronary vessel Anatomy 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 15
- 230000017531 blood circulation Effects 0.000 claims description 15
- 102000003814 Interleukin-10 Human genes 0.000 claims description 14
- 108090000174 Interleukin-10 Proteins 0.000 claims description 14
- 230000004663 cell proliferation Effects 0.000 claims description 14
- 210000002064 heart cell Anatomy 0.000 claims description 14
- 229940076144 interleukin-10 Drugs 0.000 claims description 14
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 13
- 108010036949 Cyclosporine Proteins 0.000 claims description 13
- 229930105110 Cyclosporin A Natural products 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 11
- 208000028867 ischemia Diseases 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 10
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 8
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 8
- 208000001629 Pentalogy of Cantrell Diseases 0.000 claims description 8
- 101150086694 SLC22A3 gene Proteins 0.000 claims description 8
- 206010058145 Subendocardial ischaemia Diseases 0.000 claims description 8
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 8
- 230000000735 allogeneic effect Effects 0.000 claims description 8
- 238000007675 cardiac surgery Methods 0.000 claims description 8
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 230000002107 myocardial effect Effects 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 7
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 7
- 230000001028 anti-proliverative effect Effects 0.000 claims description 7
- 229940046731 calcineurin inhibitors Drugs 0.000 claims description 7
- 239000003246 corticosteroid Substances 0.000 claims description 7
- 229960001334 corticosteroids Drugs 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 7
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 7
- 210000002464 muscle smooth vascular Anatomy 0.000 claims description 5
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims 2
- 230000000670 limiting effect Effects 0.000 abstract description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 253
- 235000018417 cysteine Nutrition 0.000 description 127
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 115
- 235000004279 alanine Nutrition 0.000 description 115
- 238000011282 treatment Methods 0.000 description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 41
- 230000000694 effects Effects 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 26
- 241000282414 Homo sapiens Species 0.000 description 25
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 24
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 24
- 208000035475 disorder Diseases 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 22
- 210000004413 cardiac myocyte Anatomy 0.000 description 22
- 241000124008 Mammalia Species 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 21
- 230000004069 differentiation Effects 0.000 description 21
- 238000002054 transplantation Methods 0.000 description 21
- 201000010099 disease Diseases 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 206010016654 Fibrosis Diseases 0.000 description 14
- 230000004761 fibrosis Effects 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 11
- 230000004044 response Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 206010043276 Teratoma Diseases 0.000 description 9
- 210000001789 adipocyte Anatomy 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000001172 regenerating effect Effects 0.000 description 9
- 238000012744 immunostaining Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 210000002242 embryoid body Anatomy 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000002460 smooth muscle Anatomy 0.000 description 7
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000288906 Primates Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000004445 quantitative analysis Methods 0.000 description 6
- 238000007634 remodeling Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 5
- 108010076667 Caspases Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
- 238000004624 confocal microscopy Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002592 echocardiography Methods 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 108010047303 von Willebrand Factor Proteins 0.000 description 4
- 102100036537 von Willebrand factor Human genes 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- 229960001134 von willebrand factor Drugs 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 description 2
- 238000000116 DAPI staining Methods 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000219726 Griffonia simplicifolia Species 0.000 description 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 102100030306 TBC1 domain family member 9 Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 208000032594 Vascular Remodeling Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 102000006783 calponin Human genes 0.000 description 2
- 108010086826 calponin Proteins 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000005966 endogenous activation Effects 0.000 description 2
- 230000004076 epigenetic alteration Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- 230000007998 vessel formation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100227322 Caenorhabditis elegans fli-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101150031329 Ets1 gene Proteins 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100026019 Interleukin-6 Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 101001027368 Mus musculus Fibroblast growth factor 9 Proteins 0.000 description 1
- 101100281205 Mus musculus Fli1 gene Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101100445499 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) erg-1 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
In an aspect, the invention relates to compositions and methods of enhancing neovascularization. In an aspect, the invention relates to compositions and methods for attenuating vascular apoptosis. In an aspect, the invention relates to compositions and methods for inhibiting vascular apoptosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Description
NEOVASCULARIZATION AND REGENERATION
CROSS REFERENCE TO RELATED PATENT APPLICATIONS
[0001] This application claims priority U.S. Provisional Application No.
61/618,280 filed March 30, 2012, which is herein incorporated by reference in its entirety, and is related to U.S. Provisional Application No. 61/617,985 filed March 30, 2012, titled "Methods and Compositions using FGF-8 to Enhance Cardiac Regeneration and Attenuate Adverse Cardiac Remodeling," by Dinendar Singla, which is herein incorporated by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] Parts of this invention were made with government support under awarded by the National Institutes of Heath. The United States government has certain rights in the invention.
BACKGROUND
CROSS REFERENCE TO RELATED PATENT APPLICATIONS
[0001] This application claims priority U.S. Provisional Application No.
61/618,280 filed March 30, 2012, which is herein incorporated by reference in its entirety, and is related to U.S. Provisional Application No. 61/617,985 filed March 30, 2012, titled "Methods and Compositions using FGF-8 to Enhance Cardiac Regeneration and Attenuate Adverse Cardiac Remodeling," by Dinendar Singla, which is herein incorporated by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] Parts of this invention were made with government support under awarded by the National Institutes of Heath. The United States government has certain rights in the invention.
BACKGROUND
[0003] Myocardial infarction (MI) leads to heart failure implicated by complex mechanisms of cardiac myocyte cell death, hypertrophy and fibrosis. The common therapeutic preferences to inhibit further deterioration of MI leading to end stage heart failure are very restricted.
While heart transplantation is required to manage end stage heart failure patients, it is not readily available. Moreover, the development, progression and pathogenesis of myocardial infarction (MI) in type II diabetes are complex and severe compared with age and sex matched non-diabetic patients.
While heart transplantation is required to manage end stage heart failure patients, it is not readily available. Moreover, the development, progression and pathogenesis of myocardial infarction (MI) in type II diabetes are complex and severe compared with age and sex matched non-diabetic patients.
[0004] Therefore, new cellular therapies to repair and regenerate injured myocardium as well as to prevent the progression of adverse cardiac remodeling are under diligent examination.
Cell therapy has emerged as a potential therapeutic approach for repairing injured myocardium. Thus far, cell transplantation in the mouse, rat, and human infarcted hearts has been studied employing a wide variety of cell types such as skeletal myoblasts, embryonic stem (ES) cells, c-kit positive cardiac stem cells, CD45+ve bone marrow stem cells, mesenchymal stem cells (MSC), and hematopoietic stem cells. Indeed, adult stem cells in clinical trials have furnished significant insights into cell transplantation;
however, their effectiveness is still in question. In contrast, ES cells have never reached clinical trials due to ethical and additional concerns. Thus, the optimal cell types for transplantation in the injured myocardium has yet to be identified.
Cell therapy has emerged as a potential therapeutic approach for repairing injured myocardium. Thus far, cell transplantation in the mouse, rat, and human infarcted hearts has been studied employing a wide variety of cell types such as skeletal myoblasts, embryonic stem (ES) cells, c-kit positive cardiac stem cells, CD45+ve bone marrow stem cells, mesenchymal stem cells (MSC), and hematopoietic stem cells. Indeed, adult stem cells in clinical trials have furnished significant insights into cell transplantation;
however, their effectiveness is still in question. In contrast, ES cells have never reached clinical trials due to ethical and additional concerns. Thus, the optimal cell types for transplantation in the injured myocardium has yet to be identified.
[0005] Despite advances in understanding the physiology and pathophysiology of cardiac dysfunction, including myocardial infarction, there is still a scarcity of compounds that are both potent, efficacious, and safe in enhancing neovascularization and regeneration of the heart following MI. These needs and other needs are satisfied by the present invention.
SUMMARY
SUMMARY
[0006] Disclosed herein is a method of enhancing neovascularization following cardiac dysfunction in a subject in need thereof, the method comprising (i) administering to the subject fibroblast growth factor-9 primed induced pluripotent stem cells; (ii) administering to the subject conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells; (iii) administering to the subject fibroblast growth factor-9;
and/or (iv) administering to the subject fibroblast growth factor-9 and fibroblast growth factor-8; and determining neovascularization in the heart.
and/or (iv) administering to the subject fibroblast growth factor-9 and fibroblast growth factor-8; and determining neovascularization in the heart.
[0007] Disclosed herein is a method of attenuating vascular apoptosis and/or apoptosis-related mechanisms following cardiac dysfunction in a subject in need thereof comprising (i) administering to the subject fibroblast growth factor-9 primed induced pluripotent stem cells;
(ii) administering to the subject conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells; (iii) administering to the subject fibroblast growth factor-9;
and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8; and determining apoptosis and/or apoptosis related mechanisms in the heart.
(ii) administering to the subject conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells; (iii) administering to the subject fibroblast growth factor-9;
and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8; and determining apoptosis and/or apoptosis related mechanisms in the heart.
[0008] Disclosed herein is a composition of enhancing neovascularization in a subject, the composition comprising (i) fibroblast growth factor-9 primed induced pluripotent stem cells, (ii) conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells;
(iii) administering to the subject fibroblast growth factor-9; and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
(iii) administering to the subject fibroblast growth factor-9; and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
[0009] Disclosed herein is a composition of attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject, the composition comprising (i) fibroblast growth factor-9 primed induced pluripotent stem cells; (ii) conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells; (iii) administering to the subject fibroblast growth factor-9; and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
[0010] Disclosed herein is a method of generating cardiac induced pluripotent stem cells, the method comprising (i) inserting one or more nucleic acid constructs capable of expressing stem-cell like factors into a cardiac cell type, wherein the stem-cell like factors comprise Oct3/4, KIf4, Sox2, c-Myc, and/or a combination thereof; and (ii) obtaining the cardiac induced pluripotent stem cells stably expressing the stem-cell like factors in the cardiac cell type.
[0011] Disclosed herein is a method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprising administering conditioned medium from induced pluripotent stem cells, wherein the conditioned medium is administered with or without fibroblast growth factor-9.
[0012] Disclosed herein is a method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprising administering fibroblast growth factor-9.
BRIEF DESCRIPTION OF THE FIGURES
BRIEF DESCRIPTION OF THE FIGURES
[0013] The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several aspects and together with the description serve to explain the principles of the invention.
[0014] Figures 1A-D shows indicia of untransfected H9c2 cells and indicia of stably transfected iPS cells.
[0015] Figures 2A-I shows that iPS cells generated from embryoid bodies differentiate into cardiac myocytes, smooth muscles cells, and endothelial cells.
[0016] Figure 3A shows that FGF-9-treated EBs stained positively for markers specific for ECs, VSMCs, and iPS cells; Figure 3B provides a quantitative analysis of ECs and VSMCs following iPS and FGF-9 treatment.
[0017] Figure 4A shows that iPS cells transplanted following MI differentiated into ECs and VSMCs in diabetic and non-diabetic mice and demonstrated neovascularization;
Figure 4B
provides a quantitative analysis of ECs (bottom panel) and VSMCs (top panel) following treatment with iPS cells.
Figure 4B
provides a quantitative analysis of ECs (bottom panel) and VSMCs (top panel) following treatment with iPS cells.
[0018] Figure 5A shows c-kit positive cell activation in neovascularization in VSMCs (actin) and ECs (CD31) in diabetic and non-diabetic mice; Figure 5B provides a quantitative analysis of positive c-kit+VSMCs (top panel) and c-kit+ECs (bottom panel) following MI
and treatment with iPS cells or FGF-9.
and treatment with iPS cells or FGF-9.
[0019] Figure 6A shows caspase activity and cell death detection following treatment with glucose, conditioned medium, FGF-9, and a combination thereof [0020] Figures 7A-F show the effect of iPS cells or FGF-9 following MI on artery/capillary formation.
[0021] Figures 8A-B show the effects of treatment with iPS cells and iPS cells with FGF-9 on cell differentiation.
[0022] Figure 9 provides a quantitative analysis of FGF-9 treatment on miR-126 expression following MI.
[0023] Figures 10A-B show that treatment with iPS cells or FGF-9 blunted remodeling and improved cardiac function following MI.
[0024] Additional advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or can be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
DESCRIPTION
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
DESCRIPTION
[0025] The present invention can be understood more readily by reference to the following detailed description of the invention and the Examples included therein.
[0026] Recently identified induced pluripotent stem cells (iPS cells) possess tremendous potential to treat heart disease, but their basic mechanisms of neovascularization in diabetic infarcted myocardium are largely unknown. Moreover, no attention has been paid to the dynamic and concurrent processes underlying post-MI neovascularization (angiogenesis and vasculogenesis), or the interaction of these processes with transplanted fibroblast growth factor-9 (FGF-9) primed neovascular committed iPS cells in non-diabetic and diabetic mice.
The role of transplanted FGF-9 primed differentiated iPS cells or their conditioned medium (CM) in the endogenous activation of c-kieve and FLK1-ve cardiac progenitor cells (CPCs) and c-kit+ F1k-1+ve progenitor cells (c-kit + FLK-1+ve-PCs) has never been determined in non-diabetic and diabetic mice.
The role of transplanted FGF-9 primed differentiated iPS cells or their conditioned medium (CM) in the endogenous activation of c-kieve and FLK1-ve cardiac progenitor cells (CPCs) and c-kit+ F1k-1+ve progenitor cells (c-kit + FLK-1+ve-PCs) has never been determined in non-diabetic and diabetic mice.
[0027] Using four (4) factors (Oct3/4, Sox2, K1f4, and c-Myc), iPS cells were generated from H9c2 cells (originally isolated from embryonic rat heart ventricular tissue).
These cells, which are referred to herein as "4F-iPS cells" or "iPS cells," have the potential to differentiate into cardiac myocytes in vitro and in vivo. Following myocardial infarction, transplanted cardiac iPS cells inhibited post-MI remodeling and demonstrated cardiac regeneration.
A. COMPOSITIONS
1. COMPOSITIONS FOR ENHANCING NEOVASCULARIZATION
These cells, which are referred to herein as "4F-iPS cells" or "iPS cells," have the potential to differentiate into cardiac myocytes in vitro and in vivo. Following myocardial infarction, transplanted cardiac iPS cells inhibited post-MI remodeling and demonstrated cardiac regeneration.
A. COMPOSITIONS
1. COMPOSITIONS FOR ENHANCING NEOVASCULARIZATION
[0028] Disclosed herein are compositions for enhancing neovascularization. In an aspect, disclosed herein is a composition for enhancing neovascularization in a subject, the composition comprising (i) fibroblast growth factor-9 primed induced pluripotent stem cells;
(ii) conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells;
(iii) fibroblast growth factor-9; and/or (iv) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8; and determining neovascularization in the heart. For example, a disclosed composition for enhancing neovascularization in a subject comprises any one of the following combinations of fibroblast growth factor-9 primed induced pluripotent stem cells (FGF-9 primed iPS cells); conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells (CM of FGF-9 primed iPS cells);
fibroblast growth factor-9 (FGF-9); and a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8 (FGF-9 and FGF-8).
(ii) conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells;
(iii) fibroblast growth factor-9; and/or (iv) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8; and determining neovascularization in the heart. For example, a disclosed composition for enhancing neovascularization in a subject comprises any one of the following combinations of fibroblast growth factor-9 primed induced pluripotent stem cells (FGF-9 primed iPS cells); conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells (CM of FGF-9 primed iPS cells);
fibroblast growth factor-9 (FGF-9); and a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8 (FGF-9 and FGF-8).
[0029] Table 1 ¨ Listing of Disclosed Compositions for Enhancing Neovascularization Components for Disclosed Compositions for Enhancing Neovascularization Comprising A Comprising BComprising D
ing C
(i.e., FGF-9 primed (i.e., CM of FGF-9 Compris (i.e., FGF-9 &
-9) e., (i FGF
iPS cells) iPS cells) . FGF-8) A B C D
A+B B+A C+A D+A
A+C B+C C+B D+B
A+D B+D C+D D+C
A+B+C B+A+C C+A+B D+A+B
A+B+D B+A+D C+A+D D+A+C
A+C+D B+C+D C+B+D D+B+C
A+B+C+D B+A+C+D C+A+B+D D+A+B+C
ing C
(i.e., FGF-9 primed (i.e., CM of FGF-9 Compris (i.e., FGF-9 &
-9) e., (i FGF
iPS cells) iPS cells) . FGF-8) A B C D
A+B B+A C+A D+A
A+C B+C C+B D+B
A+D B+D C+D D+C
A+B+C B+A+C C+A+B D+A+B
A+B+D B+A+D C+A+D D+A+C
A+C+D B+C+D C+B+D D+B+C
A+B+C+D B+A+C+D C+A+B+D D+A+B+C
[0030] Thus, as detailed in the above table, a disclosed composition for enhancing neovascularization comprises one or two or three or all four of the following:
(A) fibroblast growth factor-9 primed induced pluripotent stem cells; (B) conditioned media of fibroblast growth factor-9 primed induced pluripotent stem cells; (C) fibroblast growth factor-9; and (D) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
(A) fibroblast growth factor-9 primed induced pluripotent stem cells; (B) conditioned media of fibroblast growth factor-9 primed induced pluripotent stem cells; (C) fibroblast growth factor-9; and (D) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
[0031] In an aspect, a disclosed composition for enhancing neovascularization enhances cell engraftment. In an aspect, a disclosed composition enhances cell proliferation. In an aspect, a disclosed composition enhances cell differentiation. In an aspect, a disclosed composition enhances cardiac myocyte differentiation in iPS cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
[0032] In an aspect, a disclosed composition enhances cell proliferation, cell differentiation, and/or cell engraftment. For example, in an aspect, a disclosed composition enhances both cell engraftment and cell proliferation. In an aspect, a disclosed composition enhances both cell engraftment and cell differentiation. In an aspect, a disclosed composition enhances both cell proliferation and cell differentiation. In an aspect, a disclosed composition enhances cell engraftment, cell proliferation, and cell differentiation.
[0033] In an aspect, a disclosed composition for enhancing neovascularization enhances angiogenesis and/or vasculogenesis in the subject. For example, in an aspect, a disclosed composition enhances angiogenesis in the subject. In a further aspect, a disclosed composition enhances vasculogenesis in the subject. In an aspect, a disclosed composition enhances both angiogenesis and vasculogenesis in the subject.
[0034] In an aspect, a disclosed composition for enhancing neovascularization enhances cardiac function in the subject. In an aspect, enhancing cardiac function comprises increasing cardiac blood flow. In a further aspect, enhancing cardiac function comprises increasing cardiac capillary density. In yet another aspect, enhancing cardiac function comprises both increasing cardiac blood flow and increasing cardiac capillary density.
[0035] In an aspect, a disclosed composition for enhancing neovascularization attenuates vascular apoptosis and/or apoptosis-related mechanisms. In an aspect, the apoptosis and/or apoptosis-related mechanisms occurs in the induced pluripotent stem cells. In an aspect, the apoptosis and/or apoptosis-related mechanisms occurs in the cardiac tissue of the subject. In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms occurs in the iPS cells. In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms occurs in the cardiac tissue of the subject. In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms in both iPS
cells and the cardiac tissue of the subject.
cells and the cardiac tissue of the subject.
[0036] In an aspect, a disclosed composition for enhancing neovascularization increases miR-126 expression, decreases SPRED1 expression, and/or decreases PIK3R2 expression.
For example, a disclosed composition increases miR-126 expression and decreases SPRED1 expression. In an aspect, a disclosed composition increases miR-126 expression and decreases PIK3R2 expression. In an aspect, a disclosed composition decreases expression and decreases PIK3R2 expression. In an aspect, a disclosed composition increases miR-126 expression, decreases SPRED1 expression, and decreases PIK3R2 expression.
For example, a disclosed composition increases miR-126 expression and decreases SPRED1 expression. In an aspect, a disclosed composition increases miR-126 expression and decreases PIK3R2 expression. In an aspect, a disclosed composition decreases expression and decreases PIK3R2 expression. In an aspect, a disclosed composition increases miR-126 expression, decreases SPRED1 expression, and decreases PIK3R2 expression.
[0037] In an aspect, the conditioned media of a disclosed composition for enhancing neovascularization comprises one or more anti-apoptotic and anti-fibrotic factors. In a further aspect, the one or more anti-apoptotic and anti-fibrotic factors comprise fibroblast growth factor-8 (FGF-8), fibroblast growth factor-9 (FGF-9), interleukin-10 (IL-10), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1).
[0038] In an aspect, the iPS cells differentiate into endothelial cells and/or vascular smooth muscle cells. In an aspect, the iPS cells differentiate into endothelial cells. In an aspect, the iPS cells differentiate into vascular smooth muscle cells. In an aspect, the iPS cells differentiate into endothelial cells and into vascular smooth muscle cells. In an aspect, the iPS
cells are cardiac-committed. In an aspect, a disclosed composition enhances cardiac myocyte differentiation in iPS cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
cells are cardiac-committed. In an aspect, a disclosed composition enhances cardiac myocyte differentiation in iPS cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
[0039] In an aspect, the subject has experienced cardiac dysfunction. In an aspect, the cardiac dysfunction is a cardiac ischemia/reperfusion event. In an aspect, the ischemia/reperfusion event is myocardial infarction, myocardial ischemia, myocardial reperfusion, subendocardial ischemia, Takayasu's arteritis, atrial fibrillation, hemorrhagic stroke, an event that occurs during cardiac surgery where a heart lung machine is used such as coronary artery bypass, or an event that occurs during the preservation of an organ for transplant. In an aspect, the subject has a congenital heart defect. In an aspect, the congenital heart defect is hypoplasia or pentalogy of Cantrell.
[0040] In an aspect, a disclosed composition for enhancing neovascularization in a subject is administered to the subject prior to cardiac dysfunction. In an aspect, a disclosed composition is administered to the subject during cardiac dysfunction. In an aspect, a disclosed composition is administered to the subject following cardiac dysfunction. For example, in an aspect, a disclosed composition is administered to the subject within 10, 15, 20, 25, 30, or more minutes following cardiac dysfunction. In an aspect, a composition is administered within 1, 2, 6, 12, 18, 24, or more hour following cardiac dysfunction.
[0041] In an aspect, a disclosed composition for enhancing neovascularization in a subject is administered to the subject one or more times. For example, in an aspect, a disclosed composition is administered to the subject prior to and during cardiac dysfunction. In an aspect, a disclosed composition is administered to the subject during and following cardiac dysfunction. For example, in an aspect, a disclosed composition is administered to the subject prior to and following cardiac dysfunction. In an aspect, a disclosed composition is administered to the subject prior to, during, and following cardiac dysfunction.
[0042] In an aspect, a disclosed composition for enhancing neovascularization in a subject comprises between 5,000 and 500,000 induced pluripotent stem cells (iPS
cells). In an aspect, a disclosed composition comprises approximately 100,000 iPS cells. In an aspect, a disclosed composition comprises less than 100,000 iPS cells. In an aspect, a disclosed composition comprises more than 100,000 iPS cells.
cells). In an aspect, a disclosed composition comprises approximately 100,000 iPS cells. In an aspect, a disclosed composition comprises less than 100,000 iPS cells. In an aspect, a disclosed composition comprises more than 100,000 iPS cells.
[0043] In an aspect, a disclosed composition for enhancing neovascularization in a subject is administered to the subject in one intramyocardial injection. In an aspect, a disclosed composition is administered in two or more intramyocardial injections.
[0044] In an aspect, a disclosed composition for enhancing neovascularization in a subject in a subject is administered into a peri-infarct zone of the injured myocardium.
In an aspect, disclosed composition is administered into an infarcted zone of the injured myocardium. In an aspect, a disclosed composition is administered into both a peri-infarct zone of the injured myocardium and an infarcted zone of the injured myocardium.
In an aspect, disclosed composition is administered into an infarcted zone of the injured myocardium. In an aspect, a disclosed composition is administered into both a peri-infarct zone of the injured myocardium and an infarcted zone of the injured myocardium.
[0045] In an aspect, a disclosed composition for enhancing neovascularization in a subject comprises one or more immunosuppressive drugs. Immunosuppressive drugs are known in the art. In an aspect, the one or more immunosuppressive drugs comprise corticosteroids, calcineurin inhibitors, anti-proliferatives, and mTOR inhibitors. In an aspect, the one or more immunosuppressive drugs can be a combination of immunosuppressive drugs. In an aspect, the one or more immunosuppressive drugs is cyclosporine A.
[0046] In an aspect, the induced pluripotent stem cells (iPS cells) of a disclosed composition are obtained from an autologous source. In an aspect, the iPS cells are obtained from an allogeneic source. In an aspect, the iPS cells are obtained from a syngeneic source. In an aspect, the iPS cells are obtained from a combination of sources.
[0047] In an aspect, the induced pluripotent stem cells of a disclosed composition for enhancing neovascularization in a subject are obtained from fibroblast cells.
In a further aspect, the induced pluripotent stem cells are obtained from H9c2 cells. In an aspect, the fibroblast cells or the H9c2 cells are transfected with a vector comprising a nucleic acid molecule encoding at least one stemness factor. In an aspect, the at least one stemness factor comprises c-myc, oct 3/4, K1f4, nanog, or Sox2, or a combination thereof For example, in an aspect, the stemness factors are c-myc, oct 3/4, K1f4, and Sox2.
In a further aspect, the induced pluripotent stem cells are obtained from H9c2 cells. In an aspect, the fibroblast cells or the H9c2 cells are transfected with a vector comprising a nucleic acid molecule encoding at least one stemness factor. In an aspect, the at least one stemness factor comprises c-myc, oct 3/4, K1f4, nanog, or Sox2, or a combination thereof For example, in an aspect, the stemness factors are c-myc, oct 3/4, K1f4, and Sox2.
[0048] In an aspect, a disclosed composition for enhancing neovascularization inhibits fibrosis and/or fibrosis-related mechanisms.
[0049] In an aspect, a disclosed composition for enhancing neovascularization protects myocardium including, but not limited to human myocardium, with or without the administration of iPS cells.
[0050] In an aspect, the subject is a mammal. In an aspect, the mammal is a primate. In an aspect, the mammal is a human. In an aspect, the human is a patient. In an aspect, the subject is diabetic.
2. COMPOSITIONS FOR ATTENUATING VASCULAR APOPTOSIS
2. COMPOSITIONS FOR ATTENUATING VASCULAR APOPTOSIS
[0051] Disclosed herein is a composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject, the composition comprising (i) fibroblast growth factor-9 primed induced pluripotent stem cells; (ii) conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells; (iii) fibroblast growth factor-9;
and/or (iv) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8. For example, a disclosed composition for enhancing neovascularization in a subject comprises any one of the following combinations of fibroblast growth factor-9 primed induced pluripotent stem cells (FGF-9 primed iPS cells); conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells (CM of FGF-9 primed iPS cells);
fibroblast growth factor-9 (FGF-9); and a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8 (FGF-9 and FGF-8).
and/or (iv) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8. For example, a disclosed composition for enhancing neovascularization in a subject comprises any one of the following combinations of fibroblast growth factor-9 primed induced pluripotent stem cells (FGF-9 primed iPS cells); conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells (CM of FGF-9 primed iPS cells);
fibroblast growth factor-9 (FGF-9); and a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8 (FGF-9 and FGF-8).
[0052] Table 2. Listing of Disclosed Compositions for Attenuating Vascular Apoptosis Components for Disclosed Compositions for Attenuating Vascular Apoptosis Comprising A Comprising BComprising D
ing C
(i.e., FGF-9 primed (i.e., CM of FGF-9 Compris (i.e., FGF-9 &
-9) e., (i FGF
iPS cells) iPS cells) . FGF-8) A B C D
A+B B+A C+A D+A
A+C B+C C+B D+B
A+D B+D C+D D+C
A+B+C B+A+C C+A+B D+A+B
A+B+D B+A+D C+A+D D+A+C
A+C+D B+C+D C+B+D D+B+C
A+B+C+D B+A+C+D C+A+B+D D+A+B+C
ing C
(i.e., FGF-9 primed (i.e., CM of FGF-9 Compris (i.e., FGF-9 &
-9) e., (i FGF
iPS cells) iPS cells) . FGF-8) A B C D
A+B B+A C+A D+A
A+C B+C C+B D+B
A+D B+D C+D D+C
A+B+C B+A+C C+A+B D+A+B
A+B+D B+A+D C+A+D D+A+C
A+C+D B+C+D C+B+D D+B+C
A+B+C+D B+A+C+D C+A+B+D D+A+B+C
[0053] Thus, as detailed in the above table, a disclosed composition for attenuating vascular apoptosis comprises one or two or three or all four of the following: (A) fibroblast growth factor-9 primed induced pluripotent stem cells; (B) conditioned media of fibroblast growth factor-9 primed induced pluripotent stem cells; (C) fibroblast growth factor-9; and (D) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
[0054] In an aspect, a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms enhances angiogenesis and/or vasculogenesis in the subject.
For example, in an aspect, a disclosed composition enhances angiogenesis in the subject. In a further aspect, a disclosed composition enhances vasculogenesis in the subject. In an aspect, a disclosed composition enhances both angiogenesis and vasculogenesis in the subject.
For example, in an aspect, a disclosed composition enhances angiogenesis in the subject. In a further aspect, a disclosed composition enhances vasculogenesis in the subject. In an aspect, a disclosed composition enhances both angiogenesis and vasculogenesis in the subject.
[0055] In an aspect, a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms further enhances cardiac function in the subject.
In an aspect, enhancing cardiac function comprises increasing cardiac blood flow. In a further aspect, enhancing cardiac function comprises increasing cardiac capillary density. In yet another aspect, enhancing cardiac function comprises both increasing cardiac blood flow and increasing cardiac capillary density.
In an aspect, enhancing cardiac function comprises increasing cardiac blood flow. In a further aspect, enhancing cardiac function comprises increasing cardiac capillary density. In yet another aspect, enhancing cardiac function comprises both increasing cardiac blood flow and increasing cardiac capillary density.
[0056] In an aspect, the apoptosis and/or apoptosis-related mechanisms occurs in the induced pluripotent stem cells. In an aspect, the apoptosis and/or apoptosis-related mechanisms occurs in the cardiac tissue of the subject. In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms in the iPS cells. In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms in the cardiac tissue of the subject.
In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms in the iPS cells and the cardiac tissue of the subject.
In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms in the iPS cells and the cardiac tissue of the subject.
[0057] In an aspect, a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms increases miR-126 expression, decreases SPRED1 expression, and/or a decreases PIK3R2 expression. For example, a disclosed composition increases miR-126 expression and decreases SPRED1 expression. In an aspect, a disclosed composition increases miR-126 expression and decreases PIK3R2 expression. In an aspect, a disclosed composition decreases SPRED1 expression and decreases PIK3R2 expression. In an aspect, a disclosed composition increases miR-126 expression, decreases SPRED1 expression, and decreases PIK3R2 expression.
[0058] In an aspect, the conditioned media of a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms comprises one or more anti-apoptotic and anti-fibrotic factors. In a further aspect, the one or more anti-apoptotic and anti-fibrotic factors comprise fibroblast growth factor-8 (FGF-8), fibroblast growth factor-9 (FGF-9), interleukin-10 (IL-10), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1).
[0059] In an aspect, the iPS cells differentiate into endothelial cells and/or vascular smooth muscle cells. In an aspect, the iPS cells differentiate into endothelial cells. In an aspect, the iPS cells differentiate into vascular smooth muscle cells. In an aspect, the iPS cells differentiate into endothelial cells and vascular smooth muscle cells. In an aspect, the iPS
cells are cardiac-committed. In an aspect, a disclosed composition enhances cardiac myocyte differentiation in iPS cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
cells are cardiac-committed. In an aspect, a disclosed composition enhances cardiac myocyte differentiation in iPS cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
[0060] In an aspect, the subject has experienced cardiac dysfunction. In an aspect, the cardiac dysfunction is a cardiac ischemia/reperfusion event. In an aspect, the ischemia/reperfusion event is myocardial infarction, myocardial ischemia, myocardial reperfusion, subendocardial ischemia, Takayasu's arteritis, atrial fibrillation, hemorrhagic stroke, an event that occurs during cardiac surgery where a heart lung machine is used such as coronary artery bypass, or an event that occurs during the preservation of an organ for transplant. In an aspect, the subject has a congenital heart defect. In an aspect, the congenital heart defect is hypoplasia or pentalogy of Cantrell.
[0061] In an aspect, a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject is administered to the subject prior to cardiac dysfunction. In an aspect, a disclosed composition is administered to the subject during cardiac dysfunction. In an aspect, a disclosed composition is administered to the subject following cardiac dysfunction. For example, in an aspect, a disclosed composition is administered to the subject within 10, 15, 20, 25, 30, or more minutes following cardiac dysfunction. In an aspect, a composition is administered within 1, 2, 6, 12, 18, 24, or more hour following cardiac dysfunction.
[0062] In an aspect, a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject is administered to the subject one or more times.
For example, in an aspect, a disclosed composition is administered to the subject prior to and during cardiac dysfunction. In an aspect, a disclosed composition is administered to the subject during and following cardiac dysfunction. For example, in an aspect, a disclosed composition is administered to the subject prior to and following cardiac dysfunction. In an aspect, a disclosed composition is administered to the subject prior to, during, and following cardiac dysfunction.
For example, in an aspect, a disclosed composition is administered to the subject prior to and during cardiac dysfunction. In an aspect, a disclosed composition is administered to the subject during and following cardiac dysfunction. For example, in an aspect, a disclosed composition is administered to the subject prior to and following cardiac dysfunction. In an aspect, a disclosed composition is administered to the subject prior to, during, and following cardiac dysfunction.
[0063] In an aspect, a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject comprises between 5,000 and 500,000 induced pluripotent stem cells (iPS cells). In an aspect, a composition comprises approximately 100,000 iPS cells. In an aspect, a composition comprises less than 100,000 iPS
cells. In an aspect, a composition comprises more than 100,000 iPS cells.
cells. In an aspect, a composition comprises more than 100,000 iPS cells.
[0064] In an aspect, a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject is administered to the subject in one intramyocardial injection. In an aspect, a disclosed composition is administered in two or more intramyocardial injections.
[0065] In an aspect, a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject is administered into a peri-infarct zone of the injured myocardium. In an aspect, disclosed composition is administered into an infarcted zone of the injured myocardium. In an aspect, a disclosed composition is administered into both a peri-infarct zone of the injured myocardium and an infarcted zone of the injured myocardium.
[0066] In an aspect, a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject comprises one or more immunosuppressive drugs.
Immunosuppressive drugs are known in the art. In an aspect, the one or more immunosuppressive drugs comprise corticosteroids, calcineurin inhibitors, anti-proliferatives, and mTOR inhibitors. In an aspect, the one or more immunosuppressive drugs can be a combination of immunosuppressive drugs. In an aspect, the one or more immunosuppressive drugs is cyclosporine A.
Immunosuppressive drugs are known in the art. In an aspect, the one or more immunosuppressive drugs comprise corticosteroids, calcineurin inhibitors, anti-proliferatives, and mTOR inhibitors. In an aspect, the one or more immunosuppressive drugs can be a combination of immunosuppressive drugs. In an aspect, the one or more immunosuppressive drugs is cyclosporine A.
[0067] In an aspect, the induced pluripotent stem cells (iPS cells) of a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject are obtained from an autologous source. In an aspect, the iPS cells are obtained from an allogeneic source. In an aspect, the iPS cells are obtained from a syngeneic source. In an aspect, the iPS cells are obtained from a combination of sources.
[0068] In an aspect, the induced pluripotent stem cells of a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject are obtained from fibroblast cells. In a further aspect, the induced pluripotent stem cells are obtained from H9c2 cells. In an aspect, the fibroblast cells or the H9c2 cells are transfected with a vector comprising a nucleic acid molecule encoding at least one stemness factor. In an aspect, the at least one stemness factor comprises c-myc, oct 3/4, K1f4, nanog, or Sox2, or a combination thereof For example, in an aspect, the stemness factors are c-myc, oct 3/4, K1f4, and Sox2.
[0069] In an aspect, a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms inhibits fibrosis and/or fibrosis-related mechanisms.
[0070] In an aspect, a disclosed composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms protects myocardium including, but not limited to human myocardium, with or without the administration of iPS cells.
[0071] In an aspect, the subject is a mammal. In an aspect, the mammal is a primate. In an aspect, the mammal is a human. In an aspect, the human is a patient. In an aspect, the subject is diabetic.
3. PHARMACEUTICAL COMPOSITIONS
3. PHARMACEUTICAL COMPOSITIONS
[0072] In an aspect, the invention relates to pharmaceutical compositions comprising a disclosed composition for enhancing neovascularization. In an aspect, the invention relates to pharmaceutical compositions comprising a disclosed compositions for attenuating vascular apoptosis and/or apoptosis-related mechanisms. That is, a pharmaceutical composition can be provided comprising a therapeutically effective amount of at least one disclosed compositions and a pharmaceutically acceptable carrier.
B. METHODS COMPRISING A DISCLOSED COMPOSITION
1. ENHANCING NEOVASCULARIZATION
B. METHODS COMPRISING A DISCLOSED COMPOSITION
1. ENHANCING NEOVASCULARIZATION
[0073] Disclosed herein are methods of enhancing neovascularization. In an aspect, disclosed herein is a method of enhancing neovascularization following cardiac dysfunction in a subject, the method comprising (i) administering to the subject fibroblast growth factor-9 primed induced pluripotent stem cells; (ii) administering to the subject conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells; (iii) administering to the subject fibroblast growth factor-9; and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8. For example, in an aspect, a disclosed method of enhancing neovascularization in a subject comprises administering to the subject any one of the following combinations of fibroblast growth factor-9 primed induced pluripotent stem cells (FGF-9 primed iPS cells);
conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells (CM
of FGF-9 primed iPS cells); fibroblast growth factor-9 (FGF-9); and a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8 (FGF-9 and FGF-8).
conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells (CM
of FGF-9 primed iPS cells); fibroblast growth factor-9 (FGF-9); and a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8 (FGF-9 and FGF-8).
[0074] Table 3 ¨ Listing of Disclosed Compositions for Methods of Enhancing Neovascularization Components for Disclosed Compositions for Methods of Enhancing Neovascularization Comprising A Comprising B C C Comprising D
omprising (i.e., FGF-9 primed (i.e., CM of FGF-9( (i.e., FGF-9 &
i.e. FGF-9) iPS cells) iPS cells) , FGF-8) A B C D
A+B B+A C+A D+A
Components for Disclosed Compositions for Methods of Enhancing Neovascularization Comprising A Comprising B. i Comprising D
Comprsng C
(i.e., FGF-9 primed (i.e., CM of FGF-9 (i.e., FGF-9 &
(i.e FGF-9) iPS cells) iPS cells) ., FGF-8) A+C B+C C+B D+B
A+D B+D C+D D+C
A+B+C B+A+C C+A+B D+A+B
A+B+D B+A+D C+A+D D+A+C
A+C+D B+C+D C+B+D D+B+C
A+B+C+D B+A+C+D C+A+B+D D+A+B+C
omprising (i.e., FGF-9 primed (i.e., CM of FGF-9( (i.e., FGF-9 &
i.e. FGF-9) iPS cells) iPS cells) , FGF-8) A B C D
A+B B+A C+A D+A
Components for Disclosed Compositions for Methods of Enhancing Neovascularization Comprising A Comprising B. i Comprising D
Comprsng C
(i.e., FGF-9 primed (i.e., CM of FGF-9 (i.e., FGF-9 &
(i.e FGF-9) iPS cells) iPS cells) ., FGF-8) A+C B+C C+B D+B
A+D B+D C+D D+C
A+B+C B+A+C C+A+B D+A+B
A+B+D B+A+D C+A+D D+A+C
A+C+D B+C+D C+B+D D+B+C
A+B+C+D B+A+C+D C+A+B+D D+A+B+C
[0075] Thus, as detailed in the above table, a disclosed method comprises administering one or two or three or all four of the following: (A) fibroblast growth factor-9 primed induced pluripotent stem cells; (B) conditioned media of fibroblast growth factor-9 primed induced pluripotent stem cells; (C) fibroblast growth factor-9; and (D) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
[0076] In an aspect, a disclosed method of enhancing neovascularization comprises enhancing cell engraftment. In an aspect, a disclosed method comprises enhancing cell proliferation. In an aspect, a disclosed method comprises enhancing cell differentiation.
[0077] In an aspect, a disclosed method enhances cardiac myocyte differentiation in iPS cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
[0078] In an aspect, a disclosed method enhances cell proliferation, cell differentiation, and/or cell engraftment. For example, in an aspect, a disclosed method enhances both cell engraftment and cell proliferation. In an aspect, a disclosed method enhances both cell engraftment and cell differentiation. In an aspect, a disclosed method both cell proliferation and cell differentiation. In an aspect, a disclosed method enhances cell engraftment, cell proliferation, and cell differentiation.
[0079] In an aspect, a disclosed method enhances cardiac myocyte differentiation in iPS cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
[0080] In an aspect, a disclosed method of enhancing neovascularization comprises enhancing angiogenesis and/or vasculogenesis in the subject. For example, in an aspect, a disclosed method comprises enhancing angiogenesis in the subject. In a further aspect, a disclosed method comprises enhancing vasculogenesis in the subject. In an aspect, a disclosed method comprises both enhancing angiogenesis and vasculogenesis in the subject.
[0081] In an aspect, a disclosed method of enhancing neovascularization further comprises enhancing cardiac function in the subject. In an aspect, enhancing cardiac function comprises increasing cardiac blood flow. In a further aspect, enhancing cardiac function comprises increasing cardiac capillary density. In yet another aspect, enhancing cardiac function comprises both increasing cardiac blood flow and increasing cardiac capillary density.
[0082] In an aspect, a disclosed method of enhancing neovascularization comprises attenuating vascular apoptosis. In an aspect, the apoptosis occurs in the induced pluripotent stem cells (iPS cells). In an aspect, the apoptosis and/or apoptosis-related mechanisms occurs in the cardiac tissue of the subject. In an aspect, the apoptosis and/or apoptosis-related mechanisms occurs both in the iPS cells and cardiac tissue of the subject. In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms in the iPS
cells. In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms in the cardiac tissue of the subject. In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms in the iPS cells and the cardiac tissue of the subject.
cells. In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms in the cardiac tissue of the subject. In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms in the iPS cells and the cardiac tissue of the subject.
[0083] In an aspect, a disclosed method of enhancing neovascularization comprises increasing miR-126 expression, decreasing SPRED1 expression, and/or decreasingPIK3R2 expression. For example, a disclosed method increases miR-126 expression and decreases SPRED1 expression. In an aspect, a disclosed method increases miR-126 expression and decreases PIK3R2 expression. In an aspect, a disclosed method decreases SPRED1 expression and decreases PIK3R2 expression. In an aspect, a disclosed method increases miR-126 expression, decreases SPRED1 expression, and decreases PIK3R2 expression.
[0084] In an aspect, the conditioned media of a disclosed method of enhancing neovascularization comprises one or more anti-apoptotic and anti-fibrotic factors. In a further aspect, the one or more anti-apoptotic and anti-fibrotic factors comprise fibroblast growth factor-8 (FGF-8), fibroblast growth factor-9 (FGF-9), interleukin-10 (IL-10), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1).
[0085] In an aspect, the iPS cells of a disclosed method of enhancing neovascularization differentiate into endothelial cells and/or vascular smooth muscle cells. In an aspect, the iPS
cells differentiate into endothelial cells. In an aspect, the iPS cells differentiate into vascular smooth muscle cells. In an aspect, the iPS cells differentiate into both vascular smooth muscle cells and endothelial cells. In an aspect, the iPS cells are cardiac-committed. In an aspect, a disclosed method enhances cardiac myocyte differentiation in iPS
cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
cells differentiate into endothelial cells. In an aspect, the iPS cells differentiate into vascular smooth muscle cells. In an aspect, the iPS cells differentiate into both vascular smooth muscle cells and endothelial cells. In an aspect, the iPS cells are cardiac-committed. In an aspect, a disclosed method enhances cardiac myocyte differentiation in iPS
cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
[0086] In an aspect, the subject has experienced cardiac dysfunction. In an aspect, the cardiac dysfunction is a cardiac ischemia/reperfusion event. In an aspect, the ischemia/reperfusion event is myocardial infarction, myocardial ischemia, myocardial reperfusion, subendocardial ischemia, Takayasu's arteritis, atrial fibrillation, hemorrhagic stroke, an event that occurs during cardiac surgery where a heart lung machine is used such as coronary artery bypass, or an event that occurs during the preservation of an organ for transplant. In an aspect, the subject has a congenital heart defect. In an aspect, the congenital heart defect is hypoplasia or pentalogy of Cantrell.
[0087] In an aspect of a disclosed method of enhancing neovascularization, fibroblast growth factor-9 (FGF-9) is administered to the subject prior to the administration of the induced pluripotent stem cells (iPS cells). In an aspect, FGF-9 is administered to the subject during the administration of the iPS cells. In an aspect, FGF-9 is administered to the subject following the administration of the iPS cells. In an aspect, the administration of FGF-9 is repeated. For example, in an aspect, FGF-9 is administered to the subject prior to and during the administration of the iPS cells. In an aspect, FGF-9 is administered to the subject prior to and following the administration of the iPS cells. In an aspect, FGF-9 is administered to the subject during and following the administration of the iPS cells.
[0088] In an aspect of a disclosed method of enhancing neovascularization, a disclosed composition comprising fibroblast growth factor-8 (FGF-8) and fibroblast growth factor-9 (FGF-9) is administered to the subject prior to the administration of the induced pluripotent stem cells (iPS cells). In an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject during the administration of the iPS cells. In an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject following the administration of the iPS cells. In an aspect, the administration of a disclosed composition comprising FGF-8 and FGF-9 is repeated. For example, in an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject prior to and during the administration of the iPS cells. In an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject prior to and following the administration of the iPS
cells. In an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject during and following the administration of the iPS cells.
cells. In an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject during and following the administration of the iPS cells.
[0089] In an aspect of a disclosed method of enhancing neovascularization, the conditioned media is administered to the subject prior to the administration of the induced pluripotent stem cells (iPS cells). In an aspect, the conditioned media is administered to the subject during the administration of the iPS cells. In an aspect, the conditioned media is administered to the subject following the administration of the iPS cells. In an aspect, the administration of the conditioned media is repeated. For example, in an aspect, the conditioned media is administered to the subject prior to and during the administration of the iPS
cells. In an aspect, the conditioned media is administered to the subject prior to and following the administration of the iPS cells. In an aspect, the conditioned media is administered to the subject during and following the administration of the iPS cells.
cells. In an aspect, the conditioned media is administered to the subject prior to and following the administration of the iPS cells. In an aspect, the conditioned media is administered to the subject during and following the administration of the iPS cells.
[0090] In an aspect, a disclosed method of enhancing neovascularization comprises administering iPS cells to the subject prior to cardiac dysfunction. In an aspect, a disclosed method comprises administering iPS cells to the subject during cardiac dysfunction. In an aspect, a disclosed method comprises administering iPS cells to the subject following cardiac dysfunction. For example, in an aspect, a disclosed method comprises administering iPS cells to the subject within 10, 15, 20, 25, 30, or more minutes following cardiac dysfunction. In an aspect, a disclosed method comprises administering iPS cells to the subject within 1, 2, 6, 12, 18, 24, or more hour following cardiac dysfunction.
[0091] In an aspect of a disclosed method of enhancing neovascularization, the administration of induced pluripotent stem cells to the subject is repeated.
For example, in an aspect, a disclosed method comprises administering iPS cells to the subject prior to and during cardiac dysfunction. In an aspect, a disclosed method comprises administering iPS
cells to the subject during and following cardiac dysfunction. For example, in an aspect, a disclosed method comprises administering iPS cells to the subject prior to and following cardiac dysfunction. In an aspect, a disclosed method comprises administering iPS cells to the subject prior to, during, and following cardiac dysfunction.
For example, in an aspect, a disclosed method comprises administering iPS cells to the subject prior to and during cardiac dysfunction. In an aspect, a disclosed method comprises administering iPS
cells to the subject during and following cardiac dysfunction. For example, in an aspect, a disclosed method comprises administering iPS cells to the subject prior to and following cardiac dysfunction. In an aspect, a disclosed method comprises administering iPS cells to the subject prior to, during, and following cardiac dysfunction.
[0092] In an aspect, a disclosed method of enhancing neovascularization in a subject comprises administering between 5,000 and 500,000 induced pluripotent stem cells (iPS
cells). In an aspect, a disclosed method comprises administering approximately 100,000 iPS
cells. In an aspect, a disclosed method comprises administering less than 100,000 iPS cells. In an aspect, a disclosed method comprises administering more than 100,000 iPS
cells.
cells). In an aspect, a disclosed method comprises administering approximately 100,000 iPS
cells. In an aspect, a disclosed method comprises administering less than 100,000 iPS cells. In an aspect, a disclosed method comprises administering more than 100,000 iPS
cells.
[0093] In an aspect, a disclosed method of enhancing neovascularization comprises administering iPS cells to the subject in one intramyocardial injection. In an aspect, a disclosed method of enhancing neovascularization comprises administering iPS
cells to the subject in two or more intramyocardial injections.
cells to the subject in two or more intramyocardial injections.
[0094] In an aspect, a disclosed method of enhancing neovascularization in a subject comprises administering the iPS cells into a peri-infarct zone of the injured myocardium. In an aspect, a disclosed method of enhancing neovascularization comprises administering the iPS cells into an infarcted zone of the injured myocardium. In an aspect, a disclosed method of enhancing neovascularization in a subject comprises administering iPS cells into both a peri-infarct zone of the injured myocardium and an infarcted zone of the injured myocardium.
[0095] In an aspect, a disclosed method of enhancing neovascularization in a subject comprises administering one or more immunosuppressive drugs. Immunosuppressive drugs are known in the art. In an aspect, the one or more immunosuppressive drugs comprise corticosteroids, calcineurin inhibitors, anti-proliferatives, and mTOR
inhibitors. In an aspect, the one or more immunosuppressive drugs can be a combination of immunosuppressive drugs. In an aspect, the one or more immunosuppressive drugs is cyclosporine A.
inhibitors. In an aspect, the one or more immunosuppressive drugs can be a combination of immunosuppressive drugs. In an aspect, the one or more immunosuppressive drugs is cyclosporine A.
[0096] In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to, during, and/or following the administration of the induced pluripotent stem cells (iPS
cells). In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to the administration of iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject during the administration of iPS cells.
In an aspect, the one or more immunosuppressive drugs is administered to the subject following the administration of iPS cells. In an aspect, the administration of the one or more immunosuppressive drugs is repeated. In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to and during the administration of the iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject during and following the administration of the iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to and following the administration of the iPS cells.
cells). In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to the administration of iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject during the administration of iPS cells.
In an aspect, the one or more immunosuppressive drugs is administered to the subject following the administration of iPS cells. In an aspect, the administration of the one or more immunosuppressive drugs is repeated. In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to and during the administration of the iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject during and following the administration of the iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to and following the administration of the iPS cells.
[0097] In an aspect, the induced pluripotent stem cells (iPS cells) of a disclosed method are obtained from an autologous source. In an aspect, iPS cells are obtained from an allogeneic source. In an aspect, iPS cells are obtained from a syngeneic source. In an aspect, iPS cells are obtained from a combination of sources.
[0098] In an aspect, the iPS cells of a disclosed method of enhancing neovascularization in a subject are obtained from fibroblast cells. In a further aspect, the iPS cells are obtained from H9c2 cells. In an aspect, the fibroblast cells or the H9c2 cells are transfected with a vector comprising a nucleic acid molecule encoding at least one stemness factor. In an aspect, the at least one stemness factor comprises c-myc, oct 3/4, K1f4, nanog, or Sox2, or a combination thereof For example, in an aspect, the stemness factors are c-myc, oct 3/4, K1f4, and Sox2.
[0099] In an aspect, a disclosed method for enhancing neovascularization inhibits fibrosis and/or fibrosis-related mechanisms.
[00100] In an aspect, a disclosed method for enhancing neovascularization protects myocardium including, but not limited to human myocardium, with or without the administration of iPS cells.
[00101] In an aspect, the subject is a mammal. In an aspect, the mammal is a primate.
In an aspect, the mammal is a human. In an aspect, the human is a patient. In an aspect, the subject is diabetic.
2. ATTENUATING VASCULAR APOPTOSIS AND/OR APOPTOSIS-RELATED
MECHANISMS
In an aspect, the mammal is a human. In an aspect, the human is a patient. In an aspect, the subject is diabetic.
2. ATTENUATING VASCULAR APOPTOSIS AND/OR APOPTOSIS-RELATED
MECHANISMS
[00102] Disclosed herein are methods of attenuating vascular apoptosis and/or apoptosis-related mechanisms. In an aspect, disclosed herein is a method of attenuating vascular apoptosis and/or apoptosis-related mechanisms following cardiac dysfunction in a subject in need thereof, the method comprising (i) administering to the subject fibroblast growth factor-9 primed induced pluripotent stem cells; (ii) administering to the subject conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells; (iii) administering to the subject fibroblast growth factor-9; and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
For example, in an aspect, a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms comprises administering to the subject any one of the following combinations of fibroblast growth factor-9 primed induced pluripotent stem cells (FGF-9 primed iPS cells); conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells (CM of FGF-9 primed iPS cells); fibroblast growth factor-9 (FGF-9);
and a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8 (FGF-9 and FGF-8).
For example, in an aspect, a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms comprises administering to the subject any one of the following combinations of fibroblast growth factor-9 primed induced pluripotent stem cells (FGF-9 primed iPS cells); conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells (CM of FGF-9 primed iPS cells); fibroblast growth factor-9 (FGF-9);
and a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8 (FGF-9 and FGF-8).
[00103] Table 4 ¨ Listing of Disclosed Compositions for Methods of Attenuating Vascular Apoptosis Components for Disclosed Compositions for Methods of Attenuating Vascular Apoptosis Comprising A Comprising BComprising D
ing C
(i.e., FGF-9 primed (i.e., CM of FGF-9 Compris (i.e., FGF-9 &
-9) e., (i FGF
iPS cells) iPS cells) . FGF-8) A B C D
A+B B+A C+A D+A
A+C B+C C+B D+B
A+D B+D C+D D+C
A+B+C B+A+C C+A+B D+A+B
A+B+D B+A+D C+A+D D+A+C
A+C+D B+C+D C+B+D D+B+C
A+B+C+D B+A+C+D C+A+B+D D+A+B+C
ing C
(i.e., FGF-9 primed (i.e., CM of FGF-9 Compris (i.e., FGF-9 &
-9) e., (i FGF
iPS cells) iPS cells) . FGF-8) A B C D
A+B B+A C+A D+A
A+C B+C C+B D+B
A+D B+D C+D D+C
A+B+C B+A+C C+A+B D+A+B
A+B+D B+A+D C+A+D D+A+C
A+C+D B+C+D C+B+D D+B+C
A+B+C+D B+A+C+D C+A+B+D D+A+B+C
[00104] Thus, as detailed in the above table, a disclosed method comprises administering one or two or three or all four of the following: (A) fibroblast growth factor-9 primed induced pluripotent stem cells; (B) conditioned media of fibroblast growth factor-9 primed induced pluripotent stem cells; (C) fibroblast growth factor-9; and (D) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
[00105] In an aspect, a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms comprises enhancing angiogenesis and/or vasculogenesis in the subject. For example, in an aspect, a disclosed method comprises enhancing angiogenesis in the subject. In a further aspect, a disclosed method comprises enhancing vasculogenesis in the subject. In an aspect, a disclosed method comprises both enhancing angiogenesis and vasculogenesis in the subject.
[00106] In an aspect, a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms comprises enhancing cardiac function in the subject. In an aspect, enhancing cardiac function comprises increasing cardiac blood flow. In a further aspect, enhancing cardiac function comprises increasing cardiac capillary density. In yet another aspect, enhancing cardiac function comprises increasing cardiac blood flow and increasing cardiac capillary density.
[00107] In an aspect, the apoptosis and/or apoptosis-related mechanisms occurs in the induced pluripotent stem cells (iPS cells). In an aspect, the apoptosis and/or apoptosis-related mechanisms occurs in the cardiac tissue of the subject. In an aspect, the apoptosis and/or apoptosis-related mechanisms occurs in both the iPS cells and the cardiac tissue of the subject. In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms in the iPS cells. In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms in the cardiac tissue of the subject. In an aspect, a disclosed composition attenuates apoptosis and/or apoptosis-related mechanisms in iPS cells and the cardiac tissue of the subject.
[00108] In an aspect, a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms comprises increasing miR-126 expression, decreasing SPRED1 expression, and/or decreasing PIK3R2 expression. For example, a disclosed method increases miR-126 expression and decreases SPRED1 expression. In an aspect, a disclosed method increases miR-126 expression and decreases PIK3R2 expression. In an aspect, a disclosed method decreases SPRED1 expression and decreases PIK3R2 expression.
In an aspect, a disclosed method increases miR-126 expression, decreases SPRED1 expression, and decreases PIK3R2 expression.
In an aspect, a disclosed method increases miR-126 expression, decreases SPRED1 expression, and decreases PIK3R2 expression.
[00109] In an aspect, the conditioned media of a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms comprises one or more anti-apoptotic and anti-fibrotic factors. In a further aspect, the one or more anti-apoptotic and anti-fibrotic factors comprise fibroblast growth factor-8 (FGF-8), fibroblast growth factor-9 (FGF-9), interleukin-10 (IL-10), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1).
[00110] In an aspect, the iPS cells of a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms differentiate into endothelial cells and/or vascular smooth muscle cells. In an aspect, the iPS cells differentiate into endothelial cells. In an aspect, the iPS cells differentiate into vascular smooth muscle cells. In an aspect, the iPS
cells differentiate into both vascular smooth muscle cells and endothelial cells. In an aspect, the iPS cells are cardiac-committed. In an aspect, a disclosed method enhances cardiac myocyte differentiation in iPS cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
cells differentiate into both vascular smooth muscle cells and endothelial cells. In an aspect, the iPS cells are cardiac-committed. In an aspect, a disclosed method enhances cardiac myocyte differentiation in iPS cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
[00111] In an aspect, the subject has experienced cardiac dysfunction. In an aspect, the cardiac dysfunction is a cardiac ischemia/reperfusion event. In an aspect, the ischemia/reperfusion event is myocardial infarction, myocardial ischemia, myocardial reperfusion, subendocardial ischemia, Takayasu's arteritis, atrial fibrillation, hemorrhagic stroke, an event that occurs during cardiac surgery where a heart lung machine is used such as coronary artery bypass, or an event that occurs during the preservation of an organ for transplant. In an aspect, the subject has a congenital heart defect. In an aspect, the congenital heart defect is hypoplasia or pentalogy of Cantrell.
[00112] In an aspect of a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms, fibroblast growth factor-9 (FGF-9) is administered to the subject prior to the administration of induced pluripotent stem cells (iPS
cells). In an aspect, FGF-9 is administered to the subject during the administration of iPS cells.
In an aspect, FGF-9 is administered to the subject following the administration of iPS
cells. In an aspect, the administration of FGF-9 is repeated. For example, in an aspect, FGF-9 is administered to the subject prior to and during the administration of iPS cells. In an aspect, FGF-9 is administered to the subject prior to and following the administration of iPS
cells. In an aspect, FGF-9 is administered to the subject during and following the administration of iPS
cells.
cells). In an aspect, FGF-9 is administered to the subject during the administration of iPS cells.
In an aspect, FGF-9 is administered to the subject following the administration of iPS
cells. In an aspect, the administration of FGF-9 is repeated. For example, in an aspect, FGF-9 is administered to the subject prior to and during the administration of iPS cells. In an aspect, FGF-9 is administered to the subject prior to and following the administration of iPS
cells. In an aspect, FGF-9 is administered to the subject during and following the administration of iPS
cells.
[00113] In an aspect of a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms, a disclosed composition comprising fibroblast growth factor-8 (FGF-8) and fibroblast growth factor-9 (FGF-9) is administered to the subject prior to the administration of the induced pluripotent stem cells (iPS cells). In an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject during the administration of iPS cells. In an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject following the administration of iPS
cells. In an aspect, the administration of a disclosed composition comprising FGF-8 and FGF-9 is repeated. For example, in an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject prior to and during the administration of iPS cells. In an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject prior to and following the administration of iPS cells. In an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject during and following the administration of iPS cells.
cells. In an aspect, the administration of a disclosed composition comprising FGF-8 and FGF-9 is repeated. For example, in an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject prior to and during the administration of iPS cells. In an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject prior to and following the administration of iPS cells. In an aspect, a disclosed composition comprising FGF-8 and FGF-9 is administered to the subject during and following the administration of iPS cells.
[00114] In an aspect of a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms, the conditioned media is administered to the subject prior to the administration of the induced pluripotent stem cells (iPS cells). In an aspect, the conditioned media is administered to the subject during the administration of iPS cells. In an aspect, the conditioned media is administered to the subject following the administration of iPS cells. In an aspect, the administration of the conditioned media is repeated. For example, in an aspect, the conditioned media administered to the subject prior to and during the administration of iPS cells. In an aspect, the conditioned media is administered to the subject prior to and following the administration of iPS cells. In an aspect, the conditioned media is administered to the subject during and following the administration of iPS
cells.
cells.
[00115] In an aspect, a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms comprises administering iPS cells to the subject prior to cardiac dysfunction. In an aspect, a disclosed method comprises administering iPS cells to the subject during cardiac dysfunction. In an aspect, a disclosed method comprises administering iPS cells to the subject following cardiac dysfunction. For example, in an aspect, a disclosed method comprises administering the iPS cells to the subject within 10, 15, 20, 25, 30, or more minutes following cardiac dysfunction. In an aspect, a disclosed method comprises administering the iPS cells to the subject within 1, 2, 6, 12, 18, 24, or more hour following cardiac dysfunction.
[00116] In an aspect of a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms, the administration of induced pluripotent stem cells to the subject is repeated. For example, in an aspect, a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms comprises administering iPS
cells to the subject prior to and during cardiac dysfunction. In an aspect, a disclosed method comprises administering iPS cells to the subject during and following cardiac dysfunction. For example, in an aspect, a disclosed method comprises administering iPS cells to the subject prior to and following cardiac dysfunction. In an aspect, a disclosed method comprises administering iPS
cells to the subject prior to, during, and following cardiac dysfunction.
cells to the subject prior to and during cardiac dysfunction. In an aspect, a disclosed method comprises administering iPS cells to the subject during and following cardiac dysfunction. For example, in an aspect, a disclosed method comprises administering iPS cells to the subject prior to and following cardiac dysfunction. In an aspect, a disclosed method comprises administering iPS
cells to the subject prior to, during, and following cardiac dysfunction.
[00117] In an aspect, a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject comprises administering between 5,000 and 500,000 induced pluripotent stem cells (iPS cells). In an aspect, a disclosed method comprises administering approximately 100,000 iPS cells. In an aspect, a disclosed method comprises administering less than 100,000 iPS cells. In an aspect, a disclosed method comprises administering more than 100,000 iPS cells.
[00118] In an aspect, a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms comprises administering the iPS cells to the subject in one intramyocardial injection. In an aspect, a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms comprises administering iPS cells to the subject in two or more intramyocardial injections.
[00119] In an aspect, a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject comprises administering iPS cells into a peri-infarct zone of the injured myocardium. In an aspect, disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms comprises administering the iPS
cells into an infarcted zone of the injured myocardium. In an aspect, disclosed method comprises administering the iPS cells into both a peri-infarct zone of the injured myocardium and an infarcted zone of the injured myocardium.
cells into an infarcted zone of the injured myocardium. In an aspect, disclosed method comprises administering the iPS cells into both a peri-infarct zone of the injured myocardium and an infarcted zone of the injured myocardium.
[00120] In an aspect, a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject comprises administering one or more immunosuppressive drugs. Immunosuppressive drugs are known in the art. In an aspect, the one or more immunosuppressive drugs comprise corticosteroids, calcineurin inhibitors, anti-proliferatives, and mTOR inhibitors. In an aspect, the one or more immunosuppressive drugs can be a combination of immunosuppressive drugs. In an aspect, the one or more immunosuppressive drugs is cyclosporine A.
[00121] In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to, during, and/or following the administration of the induced pluripotent stem cells (iPS cells). In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to the administration of iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject during the administration of iPS
cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject following the administration of iPS cells. In an aspect, the administration of the one or more immunosuppressive drugs is repeated. In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to and during the administration of iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject during and following the administration of iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to and following the administration of iPS cells.
cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject following the administration of iPS cells. In an aspect, the administration of the one or more immunosuppressive drugs is repeated. In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to and during the administration of iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject during and following the administration of iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to and following the administration of iPS cells.
[00122] In an aspect, the induced pluripotent stem cells (iPS cells) of a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms are obtained from an autologous source. In an aspect, the iPS cells are obtained from an allogeneic source.
In an aspect, the iPS cells are obtained from a syngeneic source. In an aspect, the iPS cells are obtained from a combination of sources.
In an aspect, the iPS cells are obtained from a syngeneic source. In an aspect, the iPS cells are obtained from a combination of sources.
[00123] In yet another aspect, the iPS cells of a disclosed method of attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject are obtained from fibroblast cells. In a further aspect, the iPS cells are obtained from H9c2 cells. In an aspect, the fibroblast cells or the H9c2 cells are transfected with a vector comprising a nucleic acid molecule encoding at least one stemness factor. In an aspect, the at least one stemness factor comprises c-myc, oct 3/4, K1f4, nanog, or Sox2, or a combination thereof For example, in an aspect, the stemness factors are c-myc, oct 3/4, K1f4, and Sox2.
[00124] In an aspect, a disclosed method for attenuating vascular apoptosis and/or apoptosis-related mechanisms inhibits fibrosis and/or fibrosis-related mechanisms.
[00125] In an aspect, a disclosed method for attenuating vascular apoptosis and/or apoptosis-related mechanisms protects myocardium including, but not limited to human myocardium, with or without the administration of iPS cells.
[00126] In an aspect, the subject is a mammal. In an aspect, the mammal is a primate.
In an aspect, the mammal is a human. In an aspect, the human is a patient. In an aspect, the subject is diabetic.
3. GENERATING INDUCED PLURIPOTENT STEM CELLS
In an aspect, the mammal is a human. In an aspect, the human is a patient. In an aspect, the subject is diabetic.
3. GENERATING INDUCED PLURIPOTENT STEM CELLS
[00127] Disclosed herein is a method of generating cardiac induced pluripotent stem cells (iPS cells). In an aspect, the method of generating cardiac induced pluripotent stem cells comprises (i) inserting one or more nucleic acid constructs capable of expressing stem-cell like factors into a cardiac cell type, and (ii) obtaining the cardiac induced pluripotent stem cells stably expressing the stem-cell like factors in the cardiac cell type.
In an aspect, the stem-cell like factors comprise Oct3/4, KIf4, Sox2, nanog, and c-Myc, or a combination thereof In an aspect, the iPS cells differentiate into cardiac myocytes. In a further aspect, the iPS cells are cardiac-committed.
In an aspect, the stem-cell like factors comprise Oct3/4, KIf4, Sox2, nanog, and c-Myc, or a combination thereof In an aspect, the iPS cells differentiate into cardiac myocytes. In a further aspect, the iPS cells are cardiac-committed.
[00128] In an aspect, a disclosed method enhances cardiac myocyte differentiation in iPS cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
[00129] In an aspect, the iPS cells are obtained from an autologous source.
In an aspect, the iPS cells are obtained from an allogeneic source. In an aspect, the iPS cells are obtained from a syngeneic source. In yet another aspect, the iPS cells are obtained from fibroblast cells. In an aspect, the iPS cells are obtained from a combination of sources. In a further aspect, the iPS cells are obtained from H9c2 cells. In an aspect, the fibroblast cells or the H9c2 cells are transfected with a vector comprising a nucleic acid molecule encoding at least one stemness factor.
In an aspect, the iPS cells are obtained from an allogeneic source. In an aspect, the iPS cells are obtained from a syngeneic source. In yet another aspect, the iPS cells are obtained from fibroblast cells. In an aspect, the iPS cells are obtained from a combination of sources. In a further aspect, the iPS cells are obtained from H9c2 cells. In an aspect, the fibroblast cells or the H9c2 cells are transfected with a vector comprising a nucleic acid molecule encoding at least one stemness factor.
[00130] In an aspect, the disclosed induced pluripotent stem cells are used in a method of enhancing revascularization in a subject. In an aspect, the disclosed induced pluripotent stem cells are used in a method of attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject. In an aspect, the subject is a mammal. In an aspect, the mammal is a primate. In an aspect, the mammal is a human. In an aspect, the human is a patient. In an aspect, the subject has diabetes. In an aspect, the subject has experienced cardiac dysfunction.
In an aspect, the cardiac dysfunction is a cardiac ischemia/reperfusion event.
In an aspect, the ischemia/reperfusion event is myocardial infarction, myocardial ischemia, myocardial reperfusion, subendocardial ischemia, Takayasu's arteritis, atrial fibrillation, hemorrhagic stroke, an event that occurs during cardiac surgery where a heart lung machine is used such as coronary artery bypass, or an event that occurs during the preservation of an organ for transplant. In an aspect, the subject has a congenital heart defect. In an aspect, the congenital heart defect is hypoplasia or pentalogy of Cantrell.
In an aspect, the cardiac dysfunction is a cardiac ischemia/reperfusion event.
In an aspect, the ischemia/reperfusion event is myocardial infarction, myocardial ischemia, myocardial reperfusion, subendocardial ischemia, Takayasu's arteritis, atrial fibrillation, hemorrhagic stroke, an event that occurs during cardiac surgery where a heart lung machine is used such as coronary artery bypass, or an event that occurs during the preservation of an organ for transplant. In an aspect, the subject has a congenital heart defect. In an aspect, the congenital heart defect is hypoplasia or pentalogy of Cantrell.
[00131] In an aspect, the disclosed iPS cells are primed with fibroblast growth factor-9.
In an aspect, the iPS cells are administered with one or more of the following: conditioned media of fibroblast growth factor-9 primed induced pluripotent stem cells, fibroblast growth factor-9, and a disclosed composition comprising fibroblast growth factor-8 and fibroblast growth factor-9.
In an aspect, the iPS cells are administered with one or more of the following: conditioned media of fibroblast growth factor-9 primed induced pluripotent stem cells, fibroblast growth factor-9, and a disclosed composition comprising fibroblast growth factor-8 and fibroblast growth factor-9.
[00132] In an aspect, the disclosed induced pluripotent stem cells (iPS
cells) improve angiogenesis in a subject. In an aspect, the disclosed iPS cells enhance cardiac function in a subject. In an aspect, the disclosed iPS cells improve angiogenesis and enhance cardiac function in the subject. In an aspect, enhancing cardiac function comprises one or more of (i) improving left ventricular function, (ii) improving fractional shortening, (iii) improving ejection fraction, (iv) reducing end-diastolic volume, (v) decreasing left ventricular mass, and/or (vi) normalizing of heart geometry.
cells) improve angiogenesis in a subject. In an aspect, the disclosed iPS cells enhance cardiac function in a subject. In an aspect, the disclosed iPS cells improve angiogenesis and enhance cardiac function in the subject. In an aspect, enhancing cardiac function comprises one or more of (i) improving left ventricular function, (ii) improving fractional shortening, (iii) improving ejection fraction, (iv) reducing end-diastolic volume, (v) decreasing left ventricular mass, and/or (vi) normalizing of heart geometry.
[00133] In an aspect, iPS cells inhibit fibrosis and/or fibrosis-related mechanisms.
[00134] In an aspect, iPS cells protect myocardium including, but not limited to human myocardium, with or without the administration of iPS cells.
[00135] In an aspect, the disclosed induced pluripotent stem cells inhibit or decrease necrosis. In an aspect, the disclosed induced pluripotent stem cells inhibit or decrease apoptosis and/or apoptosis-related mechanisms.
4. INHIBITING VASCULAR APOPTOSIS AND/OR APOPTOSIS-RELATED MECHANISMS
4. INHIBITING VASCULAR APOPTOSIS AND/OR APOPTOSIS-RELATED MECHANISMS
[00136] Disclosed herein is a method of inhibiting vascular apoptosis. In an aspect, the method of inhibiting vascular apoptosis comprises administering to a subject conditioned medium from induced pluripotent stem cells. In an aspect, a disclosed method of inhibiting vascular apoptosis comprises administering to a subject fibroblast growth factor-9. In an aspect, the subject is a mammal. In an aspect, the mammal is a primate. In an aspect, the mammal is a human. In an aspect, the human is a patient. In an aspect, the subject is diabetic.
[00137] In an aspect, the subject has experienced cardiac dysfunction. In an aspect, the cardiac dysfunction is a cardiac ischemia/reperfusion event. In an aspect, the ischemia/reperfusion event is myocardial infarction, myocardial ischemia, myocardial reperfusion, subendocardial ischemia, Takayasu's arteritis, atrial fibrillation, hemorrhagic stroke, an event that occurs during cardiac surgery where a heart lung machine is used such as coronary artery bypass, or an event that occurs during the preservation of an organ for transplant. In an aspect, the subject has a congenital heart defect. In an aspect, the congenital heart defect is hypoplasia or pentalogy of Cantrell.
[00138] In an aspect, a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprises enhancing angiogenesis and/or vasculogenesis in the subject. For example, in an aspect, a disclosed method comprises enhancing angiogenesis in the subject. In a further aspect, a disclosed method comprises enhancing vasculogenesis in the subject. In an aspect, a disclosed method comprises both enhancing angiogenesis and vasculogenesis in the subject.
[00139] In an aspect, a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprises enhancing cardiac function in the subject. In an aspect, enhancing cardiac function comprises increasing cardiac blood flow. In a further aspect, enhancing cardiac function comprises increasing cardiac capillary density. In yet another aspect, enhancing cardiac function comprises both increasing cardiac blood flow and increasing cardiac capillary density.
[00140] In an aspect, a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms further comprises increasing miR-126 expression, decreasing SPRED1 expression, decreasingPIK3R2 expression, and/or a combination thereof For example, a disclosed method increases miR-126 expression and decreases SPRED1 expression. In an aspect, a disclosed method increases miR-126 expression and decreases PIK3R2 expression. In an aspect, a disclosed method decreases SPRED1 expression and decreases PIK3R2 expression. In an aspect, a disclosed method increases miR-expression, decreases SPRED1 expression, and decreases PIK3R2 expression.
[00141] In an aspect, the conditioned media of a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprises one or more anti-apoptotic and anti-fibrotic factors. In a further aspect, the one or more anti-apoptotic and anti-fibrotic factors comprise fibroblast growth factor-8 (FGF-8), fibroblast growth factor-9 (FGF-9), interleukin-10 (IL-10), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1).
[00142] In an aspect, a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms further comprises administering one or more of the following:
(i) fibroblast growth factor-9 primed induced pluripotent stem cells; (ii) conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells FGF-9 primed iPS cells);
(iii) fibroblast growth factor-9; and/or (iv) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
(i) fibroblast growth factor-9 primed induced pluripotent stem cells; (ii) conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells FGF-9 primed iPS cells);
(iii) fibroblast growth factor-9; and/or (iv) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
[00143] For example, in an aspect, a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprising administering to the subject conditioned medium from induced pluripotent stem cells further comprises administering (i) fibroblast growth factor-9 primed induced pluripotent stem cells (FGF-9 primed iPS
cells); (ii) fibroblast growth factor-9; and/or (iii) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8 (FGF-9 and FGF-8).
cells); (ii) fibroblast growth factor-9; and/or (iii) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8 (FGF-9 and FGF-8).
[00144] For example, in an aspect, a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprising administering to the subject FGF-9 can further comprises administering (i) fibroblast growth factor-9 primed induced pluripotent stem cells (FGF-9 primed iPS cells); (ii) conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells; and/or (iii) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8 (FGF-9 and FGF-8).
[00145] Thus, as detailed below, a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprises any combination (such as one or two or three or all four) of the following components: (A) fibroblast growth factor-9 primed induced pluripotent stem cells; (B) conditioned media of fibroblast growth factor-9 primed induced pluripotent stem cells; (C) fibroblast growth factor-9; and (D) a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
[00146] Table 5 ¨ Listing of Disclosed Compositions for Methods of Inhibiting Vascular Apoptosis Components for Disclosed Compositions for Methods of Inhibiting Vascular Apoptosis Comprising A Comprising B. i Comprising D
Comprsng C
(i.e., FGF-9 primed (i.e., CM of FGF-9 (i.e., FGF-9 &
(i.e FGF-9) iPS cells) iPS cells) ., FGF-8) A B C D
A+B B+A C+A D+A
A+C B+C C+B D+B
Components for Disclosed Compositions for Methods of Inhibiting Vascular Apoptosis Comprising A Comprising B. i Comprising D
Comprsng C
(i.e., FGF-9 primed (i.e., CM of FGF-9 (i.e., FGF-9 &
(i.e FGF-9) iPS cells) iPS cells) ., FGF-8) A+D B+D C+D D+C
A+B+C B+A+C C+A+B D+A+B
A+B+D B+A+D C+A+D D+A+C
A+C+D B+C+D C+B+D D+B+C
A+B+C+D B+A+C+D C+A+B+D D+A+B+C
Comprsng C
(i.e., FGF-9 primed (i.e., CM of FGF-9 (i.e., FGF-9 &
(i.e FGF-9) iPS cells) iPS cells) ., FGF-8) A B C D
A+B B+A C+A D+A
A+C B+C C+B D+B
Components for Disclosed Compositions for Methods of Inhibiting Vascular Apoptosis Comprising A Comprising B. i Comprising D
Comprsng C
(i.e., FGF-9 primed (i.e., CM of FGF-9 (i.e., FGF-9 &
(i.e FGF-9) iPS cells) iPS cells) ., FGF-8) A+D B+D C+D D+C
A+B+C B+A+C C+A+B D+A+B
A+B+D B+A+D C+A+D D+A+C
A+C+D B+C+D C+B+D D+B+C
A+B+C+D B+A+C+D C+A+B+D D+A+B+C
[00147] In an aspect, the iPS cells of a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms differentiate into endothelial cells and/or vascular smooth muscle cells. In an aspect, the iPS cells differentiate into endothelial cells. In an aspect, the iPS cells differentiate into vascular smooth muscle cells. In an aspect, the iPS
cells differentiate into both endothelial cells and vascular smooth muscle cells. .In an aspect, the iPS cells are cardiac-committed. In an aspect, a disclosed method enhances cardiac myocyte differentiation in iPS cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
cells differentiate into both endothelial cells and vascular smooth muscle cells. .In an aspect, the iPS cells are cardiac-committed. In an aspect, a disclosed method enhances cardiac myocyte differentiation in iPS cells or any other source of stem cells in regenerative medicine including, but not limited to, mesenchymal stem cells, adipocyte stems cells, and any other types of stem cells known to be effective by those of skill in the art. In an aspect, a disclosed composition enhances c-kit positive cells or any other endogenous heart stem cells.
[00148] In an aspect, the induced pluripotent stem cells (iPS cells) of a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms are obtained from an autologous source. In an aspect, the iPS cells are obtained from an allogeneic source.
In an aspect, the iPS cells are obtained from a syngeneic source. In an aspect, the iPS cells are obtained from a combination of sources.
In an aspect, the iPS cells are obtained from a syngeneic source. In an aspect, the iPS cells are obtained from a combination of sources.
[00149] In yet another aspect, the iPS cells of a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms in a subject are obtained from fibroblast cells.
In a further aspect, the iPS cells are obtained from H9c2 cells. In an aspect, the fibroblast cells or the H9c2 cells are transfected with a vector comprising a nucleic acid molecule encoding at least one stemness factor. In an aspect, the at least one stemness factor comprises c-myc, oct 3/4, K1f4, nanog, or Sox2, or a combination thereof For example, in an aspect, the stemness factors are c-myc, oct 3/4, K1f4, and Sox2.
In a further aspect, the iPS cells are obtained from H9c2 cells. In an aspect, the fibroblast cells or the H9c2 cells are transfected with a vector comprising a nucleic acid molecule encoding at least one stemness factor. In an aspect, the at least one stemness factor comprises c-myc, oct 3/4, K1f4, nanog, or Sox2, or a combination thereof For example, in an aspect, the stemness factors are c-myc, oct 3/4, K1f4, and Sox2.
[00150] In an aspect, the apoptosis and/or apoptosis-related mechanisms occurs in the induced pluripotent stem cells (iPS cells). In an aspect, the apoptosis and/or apoptosis-related mechanisms occurs in the cardiac tissue of the subject. In an aspect, the apoptosis and/or apoptosis-related mechanisms occurs in both the iPS cells and in the cardiac tissue of the subject. In an aspect, a disclosed method inhibits apoptosis and/or apoptosis-related mechanisms in the iPS cells. In an aspect, a disclosed method inhibits apoptosis and/or apoptosis-related mechanisms in the cardiac tissue of the subject. In an aspect, a disclosed method inhibits apoptosis and/or apoptosis-related mechanisms in both the iPS
cells and the cardiac tissue of the subject.
cells and the cardiac tissue of the subject.
[00151] In an aspect, a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprising administering iPS cells to the subject comprises administering between 5,000 and 500,000 induced pluripotent stem cells (iPS
cells). In an aspect, a disclosed method comprises administering approximately 100,000 iPS
cells. In an aspect, a disclosed method comprises administering less than 100,000 iPS
cells.
cells). In an aspect, a disclosed method comprises administering approximately 100,000 iPS
cells. In an aspect, a disclosed method comprises administering less than 100,000 iPS
cells.
[00152] In an aspect, a disclosed method comprises administering more than 100,000 iPS cells. In an aspect, iPS cells are administered to the subject in one intramyocardial injection. In an aspect, iPS cells are administered to the subject in two or more intramyocardial injections. In an aspect, iPS cells are administered into a peri-infarct zone of the injured myocardium. In an aspect, iPS cells are administered into an infarcted zone of the injured myocardium. In an aspect, iPS cells are administered into both a peri-infarct zone of the injured myocardium and an infarcted zone of the injured myocardium.
[00153] In an aspect, the administration of the conditioned media to the subject is repeated. For example, in an aspect, the conditioned media is administered to the subject prior to and during cardiac dysfunction. In an aspect, the conditioned media is administered to the subject during and following cardiac dysfunction. For example, in an aspect, the conditioned media is administered to the subject prior to and following cardiac dysfunction.
In an aspect, the conditioned media is administered to the subject prior to, during, and following cardiac dysfunction.
In an aspect, the conditioned media is administered to the subject prior to, during, and following cardiac dysfunction.
[00154] In an aspect, the administration of the FGF-9 to the subject is repeated. For example, in an aspect, the FGF-9 is administered to the subject prior to and during cardiac dysfunction. In an aspect, the FGF-9 is administered to the subject during and following cardiac dysfunction. For example, in an aspect, the FGF-9 is administered to the subject prior to and following cardiac dysfunction. In an aspect, the FGF-9 is administered to the subject prior to, during, and following cardiac dysfunction.
[00155] In an aspect of a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprising administering FGF-9 to the subject and further comprising administering one or more other components (such as, for example, fibroblast growth factor-9 primed induced pluripotent stem cells, conditioned media of fibroblast growth factor-9 primed induced pluripotent stem cells, and/or a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8), the FGF-9 is administered to the subject prior to the administration of the one or more other components. In an aspect, FGF-9 is administered to the subject during the administration of the one or more other components.
In an aspect, FGF-9 is administered to the subject following the administration of the one or more other components. In an aspect, the administration of FGF-9 is repeated.
For example, in an aspect, FGF-9 is administered to the subject prior to and during the administration of the one or more other components. In an aspect, FGF-9 is administered to the subject prior to and following the administration of the one or more other components. In an aspect, FGF-9 is administered to the subject during and following the administration of the one or more other components. In an aspect, FGF-9 is administered to the subject prior to, during, and following the administration of the one or more other components.
In an aspect, FGF-9 is administered to the subject following the administration of the one or more other components. In an aspect, the administration of FGF-9 is repeated.
For example, in an aspect, FGF-9 is administered to the subject prior to and during the administration of the one or more other components. In an aspect, FGF-9 is administered to the subject prior to and following the administration of the one or more other components. In an aspect, FGF-9 is administered to the subject during and following the administration of the one or more other components. In an aspect, FGF-9 is administered to the subject prior to, during, and following the administration of the one or more other components.
[00156] In an aspect of a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprising administering the conditioned media of fibroblast growth factor-9 primed induced pluripotent stem cells to the subject and further comprising administering one or more other components (such as, for example, fibroblast growth factor-9 primed induced pluripotent stem cells, fibroblast growth factor-9, and/or a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8), the conditioned media is administered to the subject prior to the administration of the one or more other components. In an aspect, the conditioned media is administered to the subject during the administration of the one or more other components. In an aspect, the conditioned media is administered to the subject following the administration of the one or more other components. In an aspect, the administration of the conditioned media 9 is repeated. For example, in an aspect, the conditioned media is administered to the subject prior to and during the administration of the one or more other components. In an aspect, the conditioned media is administered to the subject prior to and following the administration of the one or more other components. In an aspect, the conditioned media is administered to the subject during and following the administration of the one or more other components.
In an aspect, the conditioned media is administered to the subject prior to, during, and following the administration of the one or more other components.
In an aspect, the conditioned media is administered to the subject prior to, during, and following the administration of the one or more other components.
[00157] In an aspect, in a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprising administering to the subject FGF-9, the FGF-9 and/or the one or more other components are administered to the subject within 10, 15, 20, 25, 30, or more minutes following cardiac dysfunction. In an aspect, in a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprising administering to the subject FGF-9, the FGF-9 and/or the one or more components are administered to the within 1, 2, 6, 12, 18, 24, or more hour following cardiac dysfunction.
[00158] In an aspect, in a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprising administering to the subject the conditioned media, the conditioned media and/or the one or more other components are administered to the subject within 10, 15, 20, 25, 30, or more minutes following cardiac dysfunction. In an aspect, in a disclosed method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms comprising administering to the subject the conditioned media, the conditioned media and/or the one or more components are administered to the within 1, 2, 6, 12, 18, 24, or more hour following cardiac dysfunction.
[00159] In an aspect, a disclosed method comprise administering one or more immunosuppressive drugs. Immunosuppressive drugs are known in the art. In an aspect, the one or more immunosuppressive drugs comprise corticosteroids, calcineurin inhibitors, anti-proliferatives, and mTOR inhibitors. In an aspect, the one or more immunosuppressive drugs can be a combination of immunosuppressive drugs. In an aspect, the one or more immunosuppressive drugs is cyclosporine A. In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to, during, and/or following the administration of the induced pluripotent stem cells (iPS cells). In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to the administration of the iPS
cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject during the administration of the iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject following the administration of the iPS
cells. In an aspect, the administration of the one or more immunosuppressive drugs is repeated. In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to and during the administration of the iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject during and following the administration of the iPS
cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to and following the administration of the iPS cells.
cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject during the administration of the iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject following the administration of the iPS
cells. In an aspect, the administration of the one or more immunosuppressive drugs is repeated. In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to and during the administration of the iPS cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject during and following the administration of the iPS
cells. In an aspect, the one or more immunosuppressive drugs is administered to the subject prior to and following the administration of the iPS cells.
[00160] In an aspect, a disclosed method for attenuating vascular apoptosis and/or apoptosis-related mechanisms inhibits fibrosis and/or fibrosis-related mechanisms.
[00161] In an aspect, a disclosed method for attenuating vascular apoptosis and/or apoptosis-related mechanisms protects myocardium including, but not limited to human myocardium, with or without the administration of iPS cells.
5. NON-MEDICAL USES
5. NON-MEDICAL USES
[00162] Also disclosed herein are uses of a disclosed composition and methods as investigational and/or research tools in the development and standardization of in vitro and in vivo test systems for evaluation in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic approaches for the enhancement of neovascularization as well as for the attenuation of vascular apoptosis and/or apoptosis-related mechanisms. In an aspect, these approaches apply to subjects with cardiac dysfunction.
C. DEFINITIONS
C. DEFINITIONS
[00163] Before the present compounds, compositions, articles, systems, devices, and/or methods are disclosed and described, it is to be understood that they are not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, example methods and materials are now described.
[00164] Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or descriptions that the steps are to be limited to a specific order, it is no way intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.
[00165]
[00166] As used in the specification and the appended claims, the singular forms "a,"
"an" and "the" include plural referents unless the context clearly dictates otherwise.
"an" and "the" include plural referents unless the context clearly dictates otherwise.
[00167] The word "or" as used herein means any one member of a particular list and also includes any combination of members of that list.
[00168] Ranges can be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, a further aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as "about" that particular value in addition to the value itself For example, if the value "10" is disclosed, then "about 10" is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
[00169] As used herein, the amino acid abbreviations are conventional one letter codes for the amino acids and are expressed as follows: A, alanine; B, asparagine or aspartic acid;
C, cysteine; D aspartic acid; E, glutamate, glutamic acid; F, phenylalanine;
G, glycine; H
histidine; I isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine;
P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine; Z, glutamine or glutamic acid.
C, cysteine; D aspartic acid; E, glutamate, glutamic acid; F, phenylalanine;
G, glycine; H
histidine; I isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine;
P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine; Z, glutamine or glutamic acid.
[00170] "Peptide" as used herein refers to any peptide, oligopeptide, polypeptide, gene product, expression product, or protein. For example, a peptide can be an enzyme. A peptide is comprised of consecutive amino acids. The term "peptide" encompasses naturally occurring or synthetic molecules.
[00171] In general, the biological activity or biological action of a peptide refers to any function exhibited or performed by the peptide that is ascribed to the naturally occurring form of the peptide as measured or observed in vivo (i.e., in the natural physiological environment of the protein) or in vitro (i.e., under laboratory conditions). For example, a biological activity of caspase includes caspase enzymatic activity.
[00172] The term "enzyme" as used herein refers to any peptide that catalyzes a chemical reaction of other substances without itself being destroyed or altered upon completion of the reaction. Typically, a peptide having enzymatic activity catalyzes the formation of one or more products from one or more substrates. Such peptides can have any type of enzymatic activity including, without limitation, the enzymatic activity or enzymatic activities associated with enzymes such as those disclosed herein.
[00173] References in the specification and concluding claims to parts by weight of a particular element or component in a composition denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed. Thus, in a compound containing 2 parts by weight of component X and 5 parts by weight component Y, X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.
[00174] A weight percent (wt. %) of a component, unless specifically stated to the contrary, is based on the total weight of the formulation or composition in which the component is included.
[00175] As used herein, the terms "optional" or "optionally" means that the subsequently described event or circumstance can or can not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[00176] As used herein, the terms "transformation" and "transfection" mean the introduction of a nucleic acid, e.g., an expression vector, into a recipient cell including introduction of a nucleic acid to the chromosomal DNA of said cell. The art is familiar with various compositions, methods, techniques, etc. used to effect the introduction of a nucleic acid into a recipient cell. The art is familiar with such compositions, methods, techniques, etc for both eukaryotic and prokaryotic cells. The art is familiar with such compositions, methods, techniques, etc. for the optimization of the introduction and expression of a nucleic acid into and within a recipient cell.
[00177] As used herein, the term "subject" refers to the target of administration, e.g., an animal. Thus, the subject of the herein disclosed methods can be a vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian. Alternatively, the subject of the herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig or rodent. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.
In one aspect, the subject is a mammal. A patient refers to a subject afflicted with a disease or disorder. The term "patient" includes human and veterinary subjects. In an aspect of a disclosed method, the subject has been diagnosed with cardiac dysfunction, such as, for example, a cardiac ischemia/reperfusion event, prior to the administering step.
In one aspect, the subject is a mammal. A patient refers to a subject afflicted with a disease or disorder. The term "patient" includes human and veterinary subjects. In an aspect of a disclosed method, the subject has been diagnosed with cardiac dysfunction, such as, for example, a cardiac ischemia/reperfusion event, prior to the administering step.
[00178] As used herein, the term "treatment" refers to the medical management of a subject or a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder. In various aspects, the term covers any treatment of a subject, including a mammal (e.g., a human), and includes: (i) preventing the disease from occurring in a subject that can be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the disease, i.e., arresting its development; or (iii) relieving the disease, i.e., causing regression of the disease. In an aspect, the disease, pathological condition, or disorder is cardiac dysfunction, such as, for example, a cardiac ischemia/reperfusion event.
[00179] As used herein, the term "prevent" or "preventing" refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action. It is understood that where reduce, inhibit or prevent are used herein, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed.
[00180] As used herein, the term "diagnosed" means having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed or treated by the compounds, compositions, or methods disclosed herein. For example, "diagnosed with cardiac dysfunction" means having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed or treated by a compound or composition that alleviates or ameliorates cardiac dysfunction. As a further example, "diagnosed with a need for "improving or enhancing neovascularization" refers to having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition characterized by cardiac dysfunction and/or cardiac impairment and/or cardiac cell death wherein improving or enhancing neovascularization would be beneficial to the subject.
Such a diagnosis can be in reference to a disorder, such as myocardial infarction, and the like, as discussed herein.
Such a diagnosis can be in reference to a disorder, such as myocardial infarction, and the like, as discussed herein.
[00181] As used herein, the phrase "identified to be in need of treatment for a disorder," or the like, refers to selection of a subject based upon need for treatment of the disorder. For example, a subject can be identified as having a need for treatment of a disorder (e.g., a disorder related to cardiac dysfunction or myocardial infarction) based upon an earlier diagnosis by a person of skill and thereafter subjected to treatment for the disorder. It is contemplated that the identification can, in one aspect, be performed by a person different from the person making the diagnosis. It is also contemplated, in a further aspect, that the administration can be performed by one who subsequently performed the administration.
[00182] As used herein, the terms "administering" and "administration"
refer to any method of providing a disclosed compositions or pharmaceutical preparation comprising a disclosed composition to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, intracardiac administration, intramyocardial administration, oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can be continuous or intermittent. In various aspects, a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition. In further various aspects, a preparation can be administered prophylactically; that is, administered for prevention of a disease or condition.
refer to any method of providing a disclosed compositions or pharmaceutical preparation comprising a disclosed composition to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, intracardiac administration, intramyocardial administration, oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can be continuous or intermittent. In various aspects, a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition. In further various aspects, a preparation can be administered prophylactically; that is, administered for prevention of a disease or condition.
[00183] The term "contacting" as used herein refers to bringing a disclosed compound and a cell, target receptor, or other biological entity together in such a manner that the compound can affect the activity of the target (e.g., receptor, transcription factor, cell, etc.), either directly; i.e., by interacting with the target itself, or indirectly;
i.e., by interacting with another molecule, co-factor, factor, or protein on which the activity of the target is dependent.
i.e., by interacting with another molecule, co-factor, factor, or protein on which the activity of the target is dependent.
[00184] As used herein, the term "determining" can refer to measuring or ascertaining a quantity or an amount or a change in expression and/or activity level, e.g., of a nucleotide or transcript or polypeptide. For example, determining the amount of a disclosed transcript or polypeptide in a sample as used herein can refer to the steps that the skilled person would take to measure or ascertain some quantifiable value of the transcript or polypeptide in the sample. The art is familiar with the ways to measure an amount of the disclosed nucleotides, transcripts, polypeptides, etc.
[00185] As used herein, the term "level" refers to the amount of a target molecule in a sample, e.g., a sample from a subject. The amount of the molecule can be determined by any method known in the art and will depend in part on the nature of the molecule (i.e., gene, mRNA, cDNA, protein, enzyme, etc.). The art is familiar with quantification methods for nucleotides (e.g., genes, cDNA, mRNA, etc) as well as proteins, polypeptides, enzymes, etc.
It is understood that the amount or level of a molecule in a sample need not be determined in absolute terms, but can be determined in relative terms (e.g., when compare to a control or a sham or an untreated sample).
It is understood that the amount or level of a molecule in a sample need not be determined in absolute terms, but can be determined in relative terms (e.g., when compare to a control or a sham or an untreated sample).
[00186] As used herein, the term "prevent" or "preventing" refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action. It is understood that where reduce, inhibit or prevent are used herein, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed.
[00187] As used herein, the phrase "identified to be in need of treatment for a disorder," or the like, refers to selection of a subject based upon need for treatment of the disorder. For example, a subject can be identified as having a need for treatment of a disorder (e.g., a disorder related to cardiac dysfunction or myocardial infarction) based upon an earlier diagnosis by a person of skill and thereafter subjected to treatment for the disorder. It is contemplated that the identification can, in one aspect, be performed by a person different from the person making the diagnosis. It is also contemplated, in a further aspect, that the administration can be performed by one who subsequently performed the administration.
[00188] As used herein, the term "neovascularization" is the formation of functional microvascular networks with red blood cell perfusion [00189] As used herein, the terms "effective amount" and "amount effective"
refer to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition. For example, a "therapeutically effective amount" refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side affects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder;
the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of a compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof to make up the daily dose.
The dosage can be adjusted by the individual physician in the event of any contraindications.
Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a "prophylactically effective amount"; that is, an amount effective for prevention of a disease or condition.
refer to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition. For example, a "therapeutically effective amount" refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side affects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder;
the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of a compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof to make up the daily dose.
The dosage can be adjusted by the individual physician in the event of any contraindications.
Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a "prophylactically effective amount"; that is, an amount effective for prevention of a disease or condition.
[00190] As used herein, the terms "effective amount" and "amount effective"
refer to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition. For example, a "therapeutically effective amount" refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side affects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder;
the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts.
refer to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition. For example, a "therapeutically effective amount" refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side affects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder;
the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts.
[00191] By "modulate" is meant to alter, by increase or decrease. As used herein, a "modulator" can mean a composition that can either increase or decrease the expression level or activity level of a gene or gene product such as a peptide. Modulation in expression or activity does not have to be complete. For example, expression or activity can be modulated by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 9,-,v0 z/0, 100% or any percentage in between as compared to a control cell wherein the expression or activity of a gene or gene product has not been modulated by a composition.
[00192] As used herein, "EC50," is intended to refer to the concentration or dose of a substance (e.g., a compound or a drug) that is required for 50% enhancement or activation of a biological process, or component of a process, including a protein, subunit, organelle, ribonucleoprotein, etc. EC50 also refers to the concentration or dose of a substance that is required for 50% enhancement or activation in vivo, as further defined elsewhere herein.
Alternatively, EC50 can refer to the concentration or dose of compound that provokes a response halfway between the baseline and maximum response. The response can be measured in an in vitro or in vivo system as is convenient and appropriate for the biological response of interest. For example, the response can be measured in vitro using cultured cardiac cells or in an ex vivo organ culture system with isolated cardiac cells, e.g., cardiomyocytes, vascular smooth muscle cells, endothelial cells, etc).
Alternatively, the response can be measured in vivo using an appropriate research model such as rodent, including mice and rats. The mouse or rat can be an inbred strain with phenotypic characteristics of interest such as, for example, obesity or diabetes. As appropriate, the response can be measured in a transgenic or knockout mouse or rat wherein a gene or genes has been introduced or knocked-out, as appropriate, to replicate a disease process.
Alternatively, EC50 can refer to the concentration or dose of compound that provokes a response halfway between the baseline and maximum response. The response can be measured in an in vitro or in vivo system as is convenient and appropriate for the biological response of interest. For example, the response can be measured in vitro using cultured cardiac cells or in an ex vivo organ culture system with isolated cardiac cells, e.g., cardiomyocytes, vascular smooth muscle cells, endothelial cells, etc).
Alternatively, the response can be measured in vivo using an appropriate research model such as rodent, including mice and rats. The mouse or rat can be an inbred strain with phenotypic characteristics of interest such as, for example, obesity or diabetes. As appropriate, the response can be measured in a transgenic or knockout mouse or rat wherein a gene or genes has been introduced or knocked-out, as appropriate, to replicate a disease process.
[00193] As used herein, "IC50," is intended to refer to the concentration or dose of a substance (e.g., a compound or a drug) that is required for 50% inhibition or diminution of a biological process, or component of a process, including a protein, subunit, organelle, ribonucleoprotein, etc. IC50 also refers to the concentration or dose of a substance that is required for 50% inhibition or diminution in vivo, as further defined elsewhere herein.
Alternatively, IC50 also refers to the half maximal (50%) inhibitory concentration (IC) or inhibitory dose of a substance. The response can be measured in an in vitro or in vivo system as is convenient and appropriate for the biological response of interest. For example, the response can be measured in vitro using cultured cardiac cells or in an ex vivo organ culture system with isolated cardiac cells (e.g., cardiomyocytes, vascular smooth muscle cells, endothelial cells, etc). Alternatively, the response can be measured in vivo using an appropriate research model such as rodent, including mice and rats. The mouse or rat can be an inbred strain with phenotypic characteristics of interest such as, for example, obesity or diabetes. As appropriate, the response can be measured in a transgenic or knockout mouse or rat wherein the a gene or genes has been introduced or knocked-out, as appropriate, to replicate a disease process.
Alternatively, IC50 also refers to the half maximal (50%) inhibitory concentration (IC) or inhibitory dose of a substance. The response can be measured in an in vitro or in vivo system as is convenient and appropriate for the biological response of interest. For example, the response can be measured in vitro using cultured cardiac cells or in an ex vivo organ culture system with isolated cardiac cells (e.g., cardiomyocytes, vascular smooth muscle cells, endothelial cells, etc). Alternatively, the response can be measured in vivo using an appropriate research model such as rodent, including mice and rats. The mouse or rat can be an inbred strain with phenotypic characteristics of interest such as, for example, obesity or diabetes. As appropriate, the response can be measured in a transgenic or knockout mouse or rat wherein the a gene or genes has been introduced or knocked-out, as appropriate, to replicate a disease process.
[00194] The term "pharmaceutically acceptable" describes a material that is not biologically or otherwise undesirable, i.e., without causing an unacceptable level of undesirable biological effects or interacting in a deleterious manner. As used herein, the term "pharmaceutically acceptable carrier" refers to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like.
Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption.
Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use. Suitable inert carriers can include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.
Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like.
Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption.
Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use. Suitable inert carriers can include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.
[00195] Disclosed are the components to be used to prepare the compositions of the invention as well as the compositions themselves to be used within the methods disclosed herein. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds can not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular compound is disclosed and discussed and a number of modifications that can be made to a number of molecules including the compounds are discussed, specifically contemplated is each and every combination and permutation of the compound and the modifications that are possible unless specifically indicated to the contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D
is disclosed, then even if each is not individually recited each is individually and collectively contemplated meaning combinations, A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F
are considered disclosed. Likewise, any subset or combination of these is also disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E would be considered disclosed.
This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the compositions of the invention. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the methods of the invention.
D. EXPERIMENTAL
is disclosed, then even if each is not individually recited each is individually and collectively contemplated meaning combinations, A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F
are considered disclosed. Likewise, any subset or combination of these is also disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E would be considered disclosed.
This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the compositions of the invention. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the methods of the invention.
D. EXPERIMENTAL
[00196] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
[00197] Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in C or is at ambient temperature, and pressure is at or near atmospheric.
1. GENERAL EXPERIMENTS
a. ESTABLISHMENT OF IPS CELL LINES AND DIFFERENTIATION OF CARDIAC CELL
TYPE
1. GENERAL EXPERIMENTS
a. ESTABLISHMENT OF IPS CELL LINES AND DIFFERENTIATION OF CARDIAC CELL
TYPE
[00198] Stably transfected iPS cell lines expressing red fluorescence protein (RFP) were generated. (Park et al., 2008). H9c2 cells were transfected with an expression vector expressing mouse stemness four factors (i.e., the 4F expression vector). The four stemness factors were c-Myc, Oct 3/4, K1f4 and Sox2. Figure 1 (panel A) shows that untransfected H9c2 cells are elongated (Figure 1, left panel, scale bar = 50 p.m). Following transduction with the 4F expression vector, these cells appeared morphologically distinct (Figure 1A, right panel) from the untransduced H9c2 cells. To determine whether these four factors were present in the generated iPS cells, western blot analysis was utilized to show expression for these four stemness factors in the iPS cells. Western blot analysis did not show the presence of any one of the four factors in the untransfected H9c2 cells, but showed increased expression of 4Fs was present in transduced H9c2. (Figure 1, panel B). Next, whether generated iPS cells expressed pluripotency markers, such as alkaline phosphatase and Oct3/4, was next determined. iPS cells expressed alkaline phosphatase in 100% of growing cells.
Similar expression was observed in ES cells, which were used as a positive control (Figure 1, panel C, scale bar = 250 nm). In contrast, H9c2 cells were negative for alkaline phosphatase staining (Figure 1, panel C). Growing iPS cells were positive for the undifferentiated pluripotent marker Oct3/4, which was compared with the positive control - ES
cells (Figure 1, panel D, scale bar = 100 nm). These data indicate that generated iPS cells were reprogrammed and expressed pluripotent markers. (Singla et al., 2011) [00199] Whether the iPS cell lines retained the capability in vitro to differentiate into all three major heart cell types (i.e., cardiomyocytes, vascular smooth muscle cells and endothelial cells) present and still express the desired reporter protein was evaluated. Figure 2 shows that iPS cells formed embryoid bodies (EBs) and differentiated into cardiac myocytes, smooth muscle cells and endothelial cells. Here, EBs were differentiated for 17 days. A
beating area was stained with anti-myosin /Alexa 488 (panel A), anti-RFP/Alexa 568 (panel B) and DAPI (panel C). The merged image (panel C) shows co-expression of myosin and RFP. Smooth muscle cells were stained with anti-smooth muscle actin /Alexa 488 (panel D), anti-RFP/Alexa 568 (panel E) and DAPI (panel F). The merged image (panel F) shows overlap of expression of smooth muscle a-actin and RFP. Endothelial cells that have formed a capillary-like structure were stained with anti-von Willebrand Factor/Alexa 488 (panel G), anti-RFP/Alexa 568 (panel H) and DAPI (panel I). The merged image (panel I) shows co-expression of von Willebrand Factor and eGFP.
b. FGF-9 ENHANCEMENT OF EC AND VSMC DIFFERENTIATION FROM IPS CELLS
Similar expression was observed in ES cells, which were used as a positive control (Figure 1, panel C, scale bar = 250 nm). In contrast, H9c2 cells were negative for alkaline phosphatase staining (Figure 1, panel C). Growing iPS cells were positive for the undifferentiated pluripotent marker Oct3/4, which was compared with the positive control - ES
cells (Figure 1, panel D, scale bar = 100 nm). These data indicate that generated iPS cells were reprogrammed and expressed pluripotent markers. (Singla et al., 2011) [00199] Whether the iPS cell lines retained the capability in vitro to differentiate into all three major heart cell types (i.e., cardiomyocytes, vascular smooth muscle cells and endothelial cells) present and still express the desired reporter protein was evaluated. Figure 2 shows that iPS cells formed embryoid bodies (EBs) and differentiated into cardiac myocytes, smooth muscle cells and endothelial cells. Here, EBs were differentiated for 17 days. A
beating area was stained with anti-myosin /Alexa 488 (panel A), anti-RFP/Alexa 568 (panel B) and DAPI (panel C). The merged image (panel C) shows co-expression of myosin and RFP. Smooth muscle cells were stained with anti-smooth muscle actin /Alexa 488 (panel D), anti-RFP/Alexa 568 (panel E) and DAPI (panel F). The merged image (panel F) shows overlap of expression of smooth muscle a-actin and RFP. Endothelial cells that have formed a capillary-like structure were stained with anti-von Willebrand Factor/Alexa 488 (panel G), anti-RFP/Alexa 568 (panel H) and DAPI (panel I). The merged image (panel I) shows co-expression of von Willebrand Factor and eGFP.
b. FGF-9 ENHANCEMENT OF EC AND VSMC DIFFERENTIATION FROM IPS CELLS
[00200] Normal embryonic cardiogenesis from mesodermal tissue requires growth factors and cytokines, including fibroblast growth factors (FGFs), wnt proteins, bone morphogenic proteins (BMPs), and transforming growth factor (TGF) [3 (Singla et al., 2005).
Several cytokines have been shown to favor cell specific differentiation in mouse ES cells.
IL-3 promotes differentiation to macrophages, mast cells, or neutrophils (Wiles et al., 1991), IL-6 to erythroid lineages (Biesecker et al., 1993), retinoic acid to neurons (Slager et al., 1993), and TGFP to cardiac myocytes (Singla et al., 2005). Recombinant mouse insulin growth factor (IGF-1) was added to a suspension of undifferentiated mouse ES
cells and subsequently transplanted into mouse hearts (Kofidis et al., 2005). This study demonstrated restoration of infarcted areas (increased donor graft/infarct ratio) with increased connexin-43 expression (Kofidis et al., 2005).
Several cytokines have been shown to favor cell specific differentiation in mouse ES cells.
IL-3 promotes differentiation to macrophages, mast cells, or neutrophils (Wiles et al., 1991), IL-6 to erythroid lineages (Biesecker et al., 1993), retinoic acid to neurons (Slager et al., 1993), and TGFP to cardiac myocytes (Singla et al., 2005). Recombinant mouse insulin growth factor (IGF-1) was added to a suspension of undifferentiated mouse ES
cells and subsequently transplanted into mouse hearts (Kofidis et al., 2005). This study demonstrated restoration of infarcted areas (increased donor graft/infarct ratio) with increased connexin-43 expression (Kofidis et al., 2005).
[00201] Similarly, FGF family members play an important role in various cell signal transduction pathways associated with embryo development (Dyer et al., 2009;
Yun et al., 2010). Reports on other FGF isoforms (FGF2, FGF4, and FGF-9) indicate a potential role in angiogenesis Yun et al., 2010; Frontini et al., 2011) in the heart whereas FGF-8 has been reported to be pro-cardiac myocyte growth factor in the developing heart (Dyer et al., 2009;
Marques et al., 2008). Specifically, FGF-9 recently been reported to decrease mortality in mice following MI (Korf-Klingebiel et al., 2011). However, the role of FGF-9 or iPS cells in the injured diabetic adult heart has not yet been characterized. Therefore, whether iPS cells primed with FGF-9 increase neovascularization and regenerate the injured diabetic myocardium merits further investigation.
Yun et al., 2010). Reports on other FGF isoforms (FGF2, FGF4, and FGF-9) indicate a potential role in angiogenesis Yun et al., 2010; Frontini et al., 2011) in the heart whereas FGF-8 has been reported to be pro-cardiac myocyte growth factor in the developing heart (Dyer et al., 2009;
Marques et al., 2008). Specifically, FGF-9 recently been reported to decrease mortality in mice following MI (Korf-Klingebiel et al., 2011). However, the role of FGF-9 or iPS cells in the injured diabetic adult heart has not yet been characterized. Therefore, whether iPS cells primed with FGF-9 increase neovascularization and regenerate the injured diabetic myocardium merits further investigation.
[00202] The iPS-EB system was used to determine whether direct treatment with FGF-9 would promote EC and VSMC differentiation. EBs derived from iPS cells were treated with 0, 25, and 50 ng per mL of the bio-active form of recombinant mouse FGF-9 and were examined by microscopy from day 0 (DO) through day 14 (D14) after plating.
Figure 3A
shows that FGF-9-treated EBs stained positive for CD31 specific for ECs, smooth muscle a-actin for VSMCs, anti-RFP for iPS cells, and DAPI for nuclear staining (panel A-B).
Additionally, the bottom panel of Figure 3 shows positive staining for von Willebrand factor VIII for ECs. Figure 3B shows a histogram providing a quantitative analysis of ECs and VSMCs, demonstrating a significant increase in the number of positively stained cells at D14 following FGF-9 treatment.
C. IDENTIFICATION OF FACTORS RELEASED FROM IPS-CM
Figure 3A
shows that FGF-9-treated EBs stained positive for CD31 specific for ECs, smooth muscle a-actin for VSMCs, anti-RFP for iPS cells, and DAPI for nuclear staining (panel A-B).
Additionally, the bottom panel of Figure 3 shows positive staining for von Willebrand factor VIII for ECs. Figure 3B shows a histogram providing a quantitative analysis of ECs and VSMCs, demonstrating a significant increase in the number of positively stained cells at D14 following FGF-9 treatment.
C. IDENTIFICATION OF FACTORS RELEASED FROM IPS-CM
[00203] Whether cytokine/growth factors were present in the iPS-CMs and could provide protection from H202-induced apoptosis was examined. 69 cytokine/growth factors were analyzed with the use of Luminex technology. (Singla et al., 2008; Singla et al., 2009).
Cytoprotective proteins released into iPS-CM were present at higher levels as compared with the H9c2-CM, ES-CM, or cell culture media used as controls. Notably, FGF-9 was significantly increased in the iPS-CM as were FGF-8, IL-10, and TIMP-1.
Cytoprotective proteins released into iPS-CM were present at higher levels as compared with the H9c2-CM, ES-CM, or cell culture media used as controls. Notably, FGF-9 was significantly increased in the iPS-CM as were FGF-8, IL-10, and TIMP-1.
[00204] TABLE 6. IDENTIFICATION OF FACTORS RELEASED FROM IPS-CM
Released Control H9c2ES Cells- iPS- FGF-8-Ce11s-Comments CM
Factors # CM CM iPS-CM
FGF-9 L* 140$ 140 370 370 Pro-cardiac growth factor in embryonic heart IL-10 L L L 45 84 Anti-apoptotic factor in cardiac myocytes TIMP-1 7 19 130 380 380 Anti-apoptotic; also well known as anti-fibrotic FGF-8 Pro-cardiac growth factor in the embryonic heart; its anti-apoptotic and pro-cardiac characteristics in apoptotic cells and in iPS-EB cell culture system established herein Values are expressed as pg/mL
*L=lowest detectable dose by the assay tell culture medium used to grow ES cells d. ESTABLISHMENT OF THE MYOCARDIAL INFARCTION MODEL AND CARDIAC
NEOVASCULAR REGENERATION
Released Control H9c2ES Cells- iPS- FGF-8-Ce11s-Comments CM
Factors # CM CM iPS-CM
FGF-9 L* 140$ 140 370 370 Pro-cardiac growth factor in embryonic heart IL-10 L L L 45 84 Anti-apoptotic factor in cardiac myocytes TIMP-1 7 19 130 380 380 Anti-apoptotic; also well known as anti-fibrotic FGF-8 Pro-cardiac growth factor in the embryonic heart; its anti-apoptotic and pro-cardiac characteristics in apoptotic cells and in iPS-EB cell culture system established herein Values are expressed as pg/mL
*L=lowest detectable dose by the assay tell culture medium used to grow ES cells d. ESTABLISHMENT OF THE MYOCARDIAL INFARCTION MODEL AND CARDIAC
NEOVASCULAR REGENERATION
[00205] A previously characterized mouse MI model (Singla et al., 2006;
Singla et al., 2007; Singla et al., 2001) was used to study iPS cell transplantation. MI was produced in C57BL/6 and db/db mice by left coronary artery ligation. Immediately after coronary ligation, two intramyocardial injections of 10 uL of medium 2.5 x 104 iPS
cells were delivered into peri-infarct zone areas of the LV. (Singla et al., 2006; Singla et al., 2007;
Singla et al., 2001). iPS cells were injected in the LV of MI animals in both groups and compared with controls (Figure 4).
Singla et al., 2007; Singla et al., 2001) was used to study iPS cell transplantation. MI was produced in C57BL/6 and db/db mice by left coronary artery ligation. Immediately after coronary ligation, two intramyocardial injections of 10 uL of medium 2.5 x 104 iPS
cells were delivered into peri-infarct zone areas of the LV. (Singla et al., 2006; Singla et al., 2007;
Singla et al., 2001). iPS cells were injected in the LV of MI animals in both groups and compared with controls (Figure 4).
[00206] The fate of donor cells was determined with the use of co-immunolabeling for the donor cell marker and neovascular cell type-specific proteins. For example, an anti-smooth muscle anti-actin antibody was used to identify VSMCs, and an anti-CD31 antibody was used to identify ECs. In iPS cell transplanted hearts, anti-RFP
immunolabeling demonstrated areas of donor cell engraftment in the infarct and border zones.
Co-immunolabeling with an antibody specific for VSMCs and ECs revealed small and large artery regeneration. (Figure 4).
immunolabeling demonstrated areas of donor cell engraftment in the infarct and border zones.
Co-immunolabeling with an antibody specific for VSMCs and ECs revealed small and large artery regeneration. (Figure 4).
[00207] In Figure 4, transplanted iPS cells following MI demonstrated neovascularization (panels A-D show vascular smooth muscle cells and panels E-H show endothelial cells). Panel A shows smooth muscle cells stained with anti-smooth muscle a-actin/Alexa568, and panel E shows endothelial cells stained with anti-CD31/Alexa568.
Panels B and F show donor-derived cells stained with anti-RFP/Alexa 488 (in green) and panels C and G show nuclei stained with DAPI. The co-localization of cell type-specific markers and donor cell RFP in merged images (yellow) indicated that transplanted iPS cells became vascular smooth muscle (panel D), and endothelial cells (panel H). The arrows in panels D and H indicate enlarged areas in right hand corner. In the histogram shown in Figure 4B, the quantitative data indicate that there was a significant (p < 0.05) increase in the number of positively stained VSMCs (top panel) and ECs (bottom panel) in the MI + iPS
group as compared with MI hearts.
e. EFFECTS OF TRANSPLANTED IPS CELLS AND FGF-9 ON C-KIT+vE-CPCS
Panels B and F show donor-derived cells stained with anti-RFP/Alexa 488 (in green) and panels C and G show nuclei stained with DAPI. The co-localization of cell type-specific markers and donor cell RFP in merged images (yellow) indicated that transplanted iPS cells became vascular smooth muscle (panel D), and endothelial cells (panel H). The arrows in panels D and H indicate enlarged areas in right hand corner. In the histogram shown in Figure 4B, the quantitative data indicate that there was a significant (p < 0.05) increase in the number of positively stained VSMCs (top panel) and ECs (bottom panel) in the MI + iPS
group as compared with MI hearts.
e. EFFECTS OF TRANSPLANTED IPS CELLS AND FGF-9 ON C-KIT+vE-CPCS
[00208] MI was produced in C57BL/6 and db/db mice by left coronary artery ligation.
Cells were transplanted as described above whereas FGF-9 (1 ng/20 1.1,L in two injections) was intramyocardially injected immediately after MI in two different injections in the peri-infarct zone. After D14, we examined c-kitve cardiac progenitor cells (CPCs), CD31+ve ECs, SMa-actin and vascular cell apoptosis. Evidence of activated c-kitve cells and their co-staining with mature VSMC marker SM a-actin was identified. These findings indicated that transplanted iPS cell released factors or that FGF-9 activated c-kitve cells, which then differentiated into mature VSMCs.
Cells were transplanted as described above whereas FGF-9 (1 ng/20 1.1,L in two injections) was intramyocardially injected immediately after MI in two different injections in the peri-infarct zone. After D14, we examined c-kitve cardiac progenitor cells (CPCs), CD31+ve ECs, SMa-actin and vascular cell apoptosis. Evidence of activated c-kitve cells and their co-staining with mature VSMC marker SM a-actin was identified. These findings indicated that transplanted iPS cell released factors or that FGF-9 activated c-kitve cells, which then differentiated into mature VSMCs.
[00209] In Figure 5, panels A-D show c-kit positive cell activation in neovascularization in vascular smooth muscle and panels E-H show activated c-kitve cells and co-staining with the mature EC marker CD31. Cell type-specific immunolabeling is indicated in red for smooth muscle (panel A) with anti-smooth muscle a-actin/Alexa568, and for endothelial cells with anti-CD31/Alexa568 (panel E). Activated c-kit positive cells were identified by anti-c-kit/Alexa 488 in green (panels B and F), and nuclei were stained with DAPI in blue (panels C and G). Co-localization of cell type-specific markers were merged images (yellow) indicating that activated c-kit positive cells have become VSMCs (panel D) and ECs (panel H). The arrows in panels D and H indicate enlarged areas.
Figure 5B shows a histogram presenting a quantitative analysis of positive c-kit+VSMCs (top panel) and c-kit+ECs (bottom panel). This quantitative data shows a significantly (*p <
0.05) increased number of c-kitve +VSMCs and c-kitve +ECs in the MI + iPS and MI + FGF-9 groups as compared with MI. Moreover, a cytokine growth analysis that iPS cells secrete pro-angiogenic growth factor FGF-9 was confirmed.
f. EFFECT OF FGF-9 ON CASPASE ACTIVITY AND CELL DEATH
Figure 5B shows a histogram presenting a quantitative analysis of positive c-kit+VSMCs (top panel) and c-kit+ECs (bottom panel). This quantitative data shows a significantly (*p <
0.05) increased number of c-kitve +VSMCs and c-kitve +ECs in the MI + iPS and MI + FGF-9 groups as compared with MI. Moreover, a cytokine growth analysis that iPS cells secrete pro-angiogenic growth factor FGF-9 was confirmed.
f. EFFECT OF FGF-9 ON CASPASE ACTIVITY AND CELL DEATH
[00210] Figure 6A shows caspase activity following treatment with glucose and H202 (GH202), or glucose and iPS cell conditioned media (GHICM), or glucose and iPS
cell conditioned media and FGF-9 (GHICM+F9), or FGF-9 (F9). Control is represented by C.
cell conditioned media and FGF-9 (GHICM+F9), or FGF-9 (F9). Control is represented by C.
[00211] Figure 6B shows cell death detection following treatment with treatment with H202 (H), or glucose and H202 (GH), or glucose and H202 (GH) and iPS cell conditioned media (GHICM), or H202 and iPS cell conditioned media and FGF-9 (HICM+F9), or glucose and H202 and iPS cell conditioned media and FGF-9 (GHICM+F9), or FGF-9 (F9).
Control is represented by C. In Figure 6B, black bars indicates that H9c2 cells were treated with H202 to induce cell death while gray bars indicated that glucose was provided to the H202 treated cells.
g. FORMATION OF VESSELS FOLLOWING IPS CELL AND FGF-9 TRANSPLANTATION
Control is represented by C. In Figure 6B, black bars indicates that H9c2 cells were treated with H202 to induce cell death while gray bars indicated that glucose was provided to the H202 treated cells.
g. FORMATION OF VESSELS FOLLOWING IPS CELL AND FGF-9 TRANSPLANTATION
[00212] To determine the effect of transplanted iPS cells and FGF-9 on coronary artery formation, the total number of small, medium, and large vessels was counted using H&E and Masson's trichome staining. (See, e.g., Figure 7A showing Masson staining in db/db mice following sham-MI (panel a), MI (panel b), MI + iPS cell treatment (panel c), and MI + FGF-9 treatment (panel d). The total number of vessels in the transplanted iPS
cell and FGF-9 groups were compared with MI in both C57BL/6J and db/db mice following MI. The histogram in Figure 7B shows a significant increase in the number of vessels in the MI + iPS
cells group and the MI + FGF-9 group as compared to the MI group (* p < 0.05).
An increase in vessel formation following iPS cell or FGF-9 transplantation was confirmed.
(X9 = FGF-9).
cell and FGF-9 groups were compared with MI in both C57BL/6J and db/db mice following MI. The histogram in Figure 7B shows a significant increase in the number of vessels in the MI + iPS
cells group and the MI + FGF-9 group as compared to the MI group (* p < 0.05).
An increase in vessel formation following iPS cell or FGF-9 transplantation was confirmed.
(X9 = FGF-9).
[00213] Figure 7C shows staining for smooth muscle (anti-alpha-actin antibody) in C57BL/6J mice following MI (panel a). Figure 7C also shows TUNEL staining in panel b and DAPI staining in panel c. The merged images of shown in panel d. The histogram in Figure 7D shows a significant decrease in the % of apoptosis in the vessels in the both the C57BL/6J and db/db mice following MI and treatment with either iPS cells or FGF-9 (* p <
0.05 compared to the MI group).
0.05 compared to the MI group).
[00214] Moreover, Figure 7E shows staining for endothelial cells (anti-antibody) in C57BL/6J mice following MI (panel a). Figure 7E also shows TUNEL
staining in panel b and DAPI staining in panel c. The merged images of shown in panel d. The histogram in Figure 7F shows a significant decrease in the % of apoptosis in the capillaries in the both the C57BL/6J and db/db mice following MI and treatment with either iPS cells or FGF-9 (* p < 0.05 compared to the MI group).
h. EFFECTS OF TREATMENT WITH IPS CELLS AND IPS CELLS WITH FGF-9 ON CELL
DIFFERENTIATION
staining in panel b and DAPI staining in panel c. The merged images of shown in panel d. The histogram in Figure 7F shows a significant decrease in the % of apoptosis in the capillaries in the both the C57BL/6J and db/db mice following MI and treatment with either iPS cells or FGF-9 (* p < 0.05 compared to the MI group).
h. EFFECTS OF TREATMENT WITH IPS CELLS AND IPS CELLS WITH FGF-9 ON CELL
DIFFERENTIATION
[00215] Figure 8A shows the percentage of total stem cells positively stained for vWF8 and the total number of smooth muscle cells positively stained for vWF8 in the iPS
cell-treated group, the iPS cell-treated group with FGF-9 (25 nanograms), and the iPS-cell treated group with FGF-9 (50 nanograms). Figure 8b shows the percentage of total stem cells positively stained for CD21 and the total number of smooth muscle cells positively stained for CD21 in the iPS cell-treated group, the iPS cell-treated group with FGF-9 (25 nanograms), and the iPS-cell treated group with FGF-9 (50 nanograms).
1. EFFECTS OF FGF-9 ON MIR-126 EXPRESSION
cell-treated group, the iPS cell-treated group with FGF-9 (25 nanograms), and the iPS-cell treated group with FGF-9 (50 nanograms). Figure 8b shows the percentage of total stem cells positively stained for CD21 and the total number of smooth muscle cells positively stained for CD21 in the iPS cell-treated group, the iPS cell-treated group with FGF-9 (25 nanograms), and the iPS-cell treated group with FGF-9 (50 nanograms).
1. EFFECTS OF FGF-9 ON MIR-126 EXPRESSION
[00216] Following MI, there is a significant decrease in cardiac neovascularization.
The data presented herein show that this decrease is blunted following FGF-9 treatment.
Furthermore, the data presented herein indicate that levels of miR-126 expression significantly decreased following MI and this decrease was modulated following treatment. The histogram in Figure 9 shows a decrease in miR-126 levels in the MI group as compared to sham control. This decrease in the MI group was reversed following treatment. (*p < 0.05 v. sham and #p < 0.05 v. MI). These data indicate that miR-126 is involved in FGF-9 mediated neovascularization.
j. ECHOCARDIOGRAPHIC EVIDENCE OF IMPROVEMENT IN LV FUNCTION
The data presented herein show that this decrease is blunted following FGF-9 treatment.
Furthermore, the data presented herein indicate that levels of miR-126 expression significantly decreased following MI and this decrease was modulated following treatment. The histogram in Figure 9 shows a decrease in miR-126 levels in the MI group as compared to sham control. This decrease in the MI group was reversed following treatment. (*p < 0.05 v. sham and #p < 0.05 v. MI). These data indicate that miR-126 is involved in FGF-9 mediated neovascularization.
j. ECHOCARDIOGRAPHIC EVIDENCE OF IMPROVEMENT IN LV FUNCTION
[00217] M-mode echocardiography was used as previously reported to determine the effect of iPS cells and FGF-9 transplantation on LV size and function in C57BL/6 and db/db mice 2 weeks following MI. Figure 10 shows that iPS cell and FGF-9 treatment blunted post-MI remodeling and improved cardiac function two weeks following MI. Figure 10A
shows the fractional shortening (FS) for the iPS cells or FGF-9 treatment groups were significantly different from the MI group. (*p < 0.05). Figure 10B shows the ES for the iPS
cells or FGF-9 treatment groups were significantly different from the MI group. (*p < 0.05).
(X9 = FGF-9).
k. AVOIDANCE OF TERATOMA FORMATION
shows the fractional shortening (FS) for the iPS cells or FGF-9 treatment groups were significantly different from the MI group. (*p < 0.05). Figure 10B shows the ES for the iPS
cells or FGF-9 treatment groups were significantly different from the MI group. (*p < 0.05).
(X9 = FGF-9).
k. AVOIDANCE OF TERATOMA FORMATION
[00218] Both human and mouse ES cells form complex teratomas when engrafted into an immune deficient host, which is a characteristic of ES cells resulting from their pluripotential capacity (Damjanov 2004; Thomson et al., 1998). Teratoma formation has been considered a major potential limitation in the therapeutic use of ES cells especially when the transplanted undifferentiated number of cells is higher than 100,000 (Nussbaum et al., 2007).
A recent study suggests that intramyocardial transplantation of 1x106 ES or iPS (generated from fibroblasts) cells in the mouse heart causes teratomas (Nelson et al., 2009; Nussbaum et al., 2007). In contrast, no teratoma formation was observed with transplantation of 300,000 cells (Bhfar et al., 2002).
A recent study suggests that intramyocardial transplantation of 1x106 ES or iPS (generated from fibroblasts) cells in the mouse heart causes teratomas (Nelson et al., 2009; Nussbaum et al., 2007). In contrast, no teratoma formation was observed with transplantation of 300,000 cells (Bhfar et al., 2002).
[00219] The transplantation of 3x104 undifferentiated ES cells did not result in the formation of teratomas after 2 (Singla et al., 2006) and 4 weeks. Importantly, generated iPS
cells from various cell sources might have varied in their epigenetic alterations; therefore formation of teratomas may vary. No teratoma formation was observed in the infarcted heart following H9c2 cell-induced iPS cell transplantation (5x104 undifferentiated iPS cells) (Singla et al., 2011). Noticeably, the number of transplanted iPS cells was dramatically less compared with the studies reporting teratoma formation (i.e., range varies from 100,000 to one million undifferentiated ES or iPS cells) (Nussbaum et al., 2007).
1. EXAMINATION OF IMMUNOGENICITY OF IPS CELLS
cells from various cell sources might have varied in their epigenetic alterations; therefore formation of teratomas may vary. No teratoma formation was observed in the infarcted heart following H9c2 cell-induced iPS cell transplantation (5x104 undifferentiated iPS cells) (Singla et al., 2011). Noticeably, the number of transplanted iPS cells was dramatically less compared with the studies reporting teratoma formation (i.e., range varies from 100,000 to one million undifferentiated ES or iPS cells) (Nussbaum et al., 2007).
1. EXAMINATION OF IMMUNOGENICITY OF IPS CELLS
[00220] iPS cells from various sources may vary in their epigenetic alterations (Kim et al., 2010). One study suggested that iPS cells generated from fibroblasts using retroviral and episomal approaches are immunogenic in nature (Zhao et al., 2011). However, generated iPS
cells by the episomal approach were less immunogenic compared with the cells generated by the retroviral approach (Zhao et al., 2011). iPS cells generated from H9c2 cells using plasmid transfection were used herein, but the immunogenicity of these cells is not well understood.
Importantly, the method, the number of cells, and the location of injections described herein differ from recent reports on the immunogenicity of iPS cells (Zhao et al., 2011). Moreover, ES cells transplanted in the sheep heart were compared with and without the immunosuppressant drug cyclosporine A, suggesting there was engraftment and cardiac regeneration in both groups (Menard et al., 2005).
2. DETERMINATION OF WHETHER TRANSPLANTED FGF-9 PRIMED IPS CELLS
ATTENUATE VASCULAR CELL APOPTOSIS AND ENHANCE NEOVASCULAR REPAIR
AND REGENERATION FOLLOWING MI
cells by the episomal approach were less immunogenic compared with the cells generated by the retroviral approach (Zhao et al., 2011). iPS cells generated from H9c2 cells using plasmid transfection were used herein, but the immunogenicity of these cells is not well understood.
Importantly, the method, the number of cells, and the location of injections described herein differ from recent reports on the immunogenicity of iPS cells (Zhao et al., 2011). Moreover, ES cells transplanted in the sheep heart were compared with and without the immunosuppressant drug cyclosporine A, suggesting there was engraftment and cardiac regeneration in both groups (Menard et al., 2005).
2. DETERMINATION OF WHETHER TRANSPLANTED FGF-9 PRIMED IPS CELLS
ATTENUATE VASCULAR CELL APOPTOSIS AND ENHANCE NEOVASCULAR REPAIR
AND REGENERATION FOLLOWING MI
[00221] Diabetes mellitus (Type II) combined with MI leads to severe cardiac and vascular remodeling, which is a complex, dynamic, and time-dependent process (Glass et al., 2010; Abel 2005; Amos et al., 1997). Recently, neovascularization has been achieved in MI
with transplanted endothelial progenitor cells (EPCs) isolated from peripheral blood as well as adult and ES cell sources (Jujo et al., 2008; Tillmanns et al., 2008;
Urbanket et al., 2003).
Mobilization of EPCs in pigs, mouse, and rat models of MI demonstrate an increase in capillary density and improved heart function (Jujo et al., 2008; Tillmanns et al., 2008;
Urbanket et al., 2003). Next, experimental evidence indicate that in diabetic animals increased blood glucose levels inducing oxidative stress lead to cardiac and vascular apoptosis, hypertrophy, and vascular remodeling (Abel 2005; Urbanek 2005).
Angiogenesis abnormalities have been shown to be present in the infarcted non-diabetic and diabetic heart (Fatma et al., 2010; Abel 2005; Urbanek et al., 2005) How much neovascularization can be achieved in the infarcted non-diabetic and diabetic hearts following transplantation of iPS
cells primed with pro-angiogeneic factor FGF-9 is unknown (1) DETERMINATION OF THE EFFECTS OF FGF-9 PRIMED IPS CELLS ON
NEOVASCULAR REGENERATION IN NON-DIABETIC AND DIABETIC MICE
FOLLOWING MI
with transplanted endothelial progenitor cells (EPCs) isolated from peripheral blood as well as adult and ES cell sources (Jujo et al., 2008; Tillmanns et al., 2008;
Urbanket et al., 2003).
Mobilization of EPCs in pigs, mouse, and rat models of MI demonstrate an increase in capillary density and improved heart function (Jujo et al., 2008; Tillmanns et al., 2008;
Urbanket et al., 2003). Next, experimental evidence indicate that in diabetic animals increased blood glucose levels inducing oxidative stress lead to cardiac and vascular apoptosis, hypertrophy, and vascular remodeling (Abel 2005; Urbanek 2005).
Angiogenesis abnormalities have been shown to be present in the infarcted non-diabetic and diabetic heart (Fatma et al., 2010; Abel 2005; Urbanek et al., 2005) How much neovascularization can be achieved in the infarcted non-diabetic and diabetic hearts following transplantation of iPS
cells primed with pro-angiogeneic factor FGF-9 is unknown (1) DETERMINATION OF THE EFFECTS OF FGF-9 PRIMED IPS CELLS ON
NEOVASCULAR REGENERATION IN NON-DIABETIC AND DIABETIC MICE
FOLLOWING MI
[00222] These experiments assess the effects of FGF-9 primed iPS cells following transplantation in infarcted myocardium (non-diabetic and diabetic mice) on stem cell survival, engraftment, and differentiation into neovascular cell types. An established mouse myocardial infarction (MI) model (Singla et al., 2006; Singla et al., 2007;
Singla et al., 2011) to inject RFP labeled differentiated iPS cells primed with FGF-9 (total of 1x105 cellsin two different intramyocardial injections in the peri-infarct zone of the infarcted heart. For example, differentiated iPS, ES cells, fibroblast reprogrammed iPS cells, H9c2 cells, FGF-9 (1 ng/20 pL in two injections or 50 ng/mL, or cell culture medium (as a control) are injected The subsequent effects on neovascularization are quantified.
Singla et al., 2011) to inject RFP labeled differentiated iPS cells primed with FGF-9 (total of 1x105 cellsin two different intramyocardial injections in the peri-infarct zone of the infarcted heart. For example, differentiated iPS, ES cells, fibroblast reprogrammed iPS cells, H9c2 cells, FGF-9 (1 ng/20 pL in two injections or 50 ng/mL, or cell culture medium (as a control) are injected The subsequent effects on neovascularization are quantified.
[00223] C57BL/6 and db/db (Jackson Laboratories) mice are used and the mice are separated into groups receiving or not receiving Cyclosporin A. Animals are treated with cyclosporine A (250-300 mg/kg) for 5 days before cell transplantation and are treated with cyclosporine A for 28 days after cell transplantation (see, e.g., Menard et al., 2005; Giralt et al., 1997). Drug dose are increased or decreased based on average cyclosporine serum concentration of 300-400 ng/L (Menard et al., 2005; Giralt et al., 1997).
Moreover, before and after MI, db/db mice are regularly monitored for glucose and given insulin injection (0.75 U/kg i.p. as reported (Kobayashi et al., 2008) if glucose levels exceed 350 25 mg/dL to eliminate the variation of observed differences due to glucose levels. Animals are killed humanely at short-term (72 hrs and 14 days) and long-term (3, 6, 12, and 16 weeks) for histological, immunohistochemistry, and physiological (blood flow) analysis.
Moreover, before and after MI, db/db mice are regularly monitored for glucose and given insulin injection (0.75 U/kg i.p. as reported (Kobayashi et al., 2008) if glucose levels exceed 350 25 mg/dL to eliminate the variation of observed differences due to glucose levels. Animals are killed humanely at short-term (72 hrs and 14 days) and long-term (3, 6, 12, and 16 weeks) for histological, immunohistochemistry, and physiological (blood flow) analysis.
[00224] FGF-9 primed-iPS cells are treated as follows. FGF-9 (50 ng/mL) is added to the iPS cells in the differentiation medium (a medium that does not contain iPS cell self-renewal growth factors such as activin A, leukemia inhibitory factor and mouse embryonic fibroblast condition medium) for 48 hours. These iPS cells are considered as FGF-9 primed differentiated iPS cells. Control iPS or ES cells are cultured for 48 hrs in a differentiation medium without FGF-9. Infiltration of T-cells is determined using anti-CD3 and anti-CD4 antibodies (Zhao et al., 2011). H&E stained sections are examined to identify the presence of any inflammatory cells. Additionally, heart sections are analyzed to determine the effect of FGF-9-iPS cells on capillary density and formation of coronary arteries. Heart function is examined via echocardiography (Singla et al., 2006; Singla et al., 2011) (2) DETERMINATION OF TOTAL NUMBER OF TRANSPLANTED FGF-9 PRIMED
IPS CELLS ENGRAFTMENT FOLLOWING MI
IPS CELLS ENGRAFTMENT FOLLOWING MI
[00225] Serial sections containing right ventricular (RV), LV free wall, and interventricular septum are immunostained for RFP (Evrogen, Russia), Oct3/4, or Sox2 (Santa Cruz Biotechnology) to determine early engraftment up to 24 hrs. Cells that stain positive for RFP, but not for Oct3/4 or Sox2 antibody, are considered as non-engrafted iPS
cells. Sections are counter-stained with DAPI (Sigma) to delineate the nuclei.
Fluorescence microscopy is used to acquire images. NIH image J processing and analysis software are employed for these analyses.
(3) DETERMINATION OF PROLIFERATION OF ENGRAFTED CELL
PROLIFERATION FOLLOWING MI
cells. Sections are counter-stained with DAPI (Sigma) to delineate the nuclei.
Fluorescence microscopy is used to acquire images. NIH image J processing and analysis software are employed for these analyses.
(3) DETERMINATION OF PROLIFERATION OF ENGRAFTED CELL
PROLIFERATION FOLLOWING MI
[00226] To determine the number of engrafted iPS cells that have started EC
and VSMC proliferation, BrdU (50 mg/kg body weight, i.p (Beltrami et al., 2003) is administered. BrdU identifies nuclei in S phase in order to label actively dividing cells.
Active cell growth of engrafted cells is identified using double-label immunostaining for RFP
and BrdU (Dako) antibodies. RFP identifies donor engrafted cells whereas BrdU
labels DNA
synthesizing cells. Furthermore, to determine how many cells have started cell division and cell types at any given time, double-label immunostaining is performed using a Ki-67 antibody (Dako) and an RFP antibody. Ki-67 is a nuclear antigen, which is associated with cell division and labels proliferating cells (G1-, S-, G2-phase and mitosis), but not in quiescent or resting cells (GO-phase), and as stated above, RFP antibodies identify donor grafted cells. Slides are analyzed using fluorescence (Olympus) and confocal microscopy.
and VSMC proliferation, BrdU (50 mg/kg body weight, i.p (Beltrami et al., 2003) is administered. BrdU identifies nuclei in S phase in order to label actively dividing cells.
Active cell growth of engrafted cells is identified using double-label immunostaining for RFP
and BrdU (Dako) antibodies. RFP identifies donor engrafted cells whereas BrdU
labels DNA
synthesizing cells. Furthermore, to determine how many cells have started cell division and cell types at any given time, double-label immunostaining is performed using a Ki-67 antibody (Dako) and an RFP antibody. Ki-67 is a nuclear antigen, which is associated with cell division and labels proliferating cells (G1-, S-, G2-phase and mitosis), but not in quiescent or resting cells (GO-phase), and as stated above, RFP antibodies identify donor grafted cells. Slides are analyzed using fluorescence (Olympus) and confocal microscopy.
[00227] Cell stage differentiation is determined. Using double or triple-label immunostaining to detect donor cells (RFP antibody) and early, late, and mature differentiated EC cell types using their marker cell specific antibodies, the number of early and mature endothelial cells that form following engraftment at various time points following MI is assessed. If cells stain positive with CD14+ or CD1a+ antibodies and are negative for vWF antibody staining, then these cells are considered early EPCs. If cells stain positively for CD34+ or CD133+ antibodies and are negative for vWF antibody staining, then these cells are considered late EPCs Mature endothelial cells are identified with antibodies such as factor VIII antibody (Sigma), CD31/PECAM-1 (Santa Cruz), and Griffonia simplicifolia lectin (Sigma).
[00228] Reports state that EPCs have the potential to differentiate into ECs and VSMCs. To confirm that EPCs differentiated from transplanted iPS cells are also positive with both newly formed EC and VSM progenitor cells, sections are immunostained with endothelial and smooth muscle specific markers (e.g., FLK-1NEGF-R2, CD34, VEcad, and endoglin). Sections are stained with respective FITC or rhodamine-conjugated secondary antibodies and counterstained with DAPI for nuclear visualization. Slides are analyzed using Olympus and confocal microscopy. Western blotting and RT-PCR are be used to determine the SM cell markers such as SM-MHC-11, calponin and 5M22 alpha. The early and late EPC
marker antibodies are commercially available (Krenning et al., 2008).
(4) IDENTIFICATION OF CORONARY ARTERY FORMATION FOLLOWING MI
marker antibodies are commercially available (Krenning et al., 2008).
(4) IDENTIFICATION OF CORONARY ARTERY FORMATION FOLLOWING MI
[00229] New cell differentiation and capillary and coronary artery formation are determined using double-label immunostaining to detect donor cells (RFP
antibody) and differentiated cell types using neovascular cell specific antibodies.
Endothelial cells are identified using cell specific antibodies such as factor VIII antibody (Sigma), CD31/PECAM-1 (Santa Cruz), and Griffonia simplicifolia lectin (sigma). For the identification of smooth muscle cells, a-smooth muscle (SM) actin (Sigma), SM22a, calponin, and SM-myosin heavy chain (MHC)-11 antibodies are used. Sections are stained with respective FITC
or rhodamine conjugated secondary antibodies and counterstained with DAPI for nuclear visualization.
Slides are analyzed using confocal microscopy.
antibody) and differentiated cell types using neovascular cell specific antibodies.
Endothelial cells are identified using cell specific antibodies such as factor VIII antibody (Sigma), CD31/PECAM-1 (Santa Cruz), and Griffonia simplicifolia lectin (sigma). For the identification of smooth muscle cells, a-smooth muscle (SM) actin (Sigma), SM22a, calponin, and SM-myosin heavy chain (MHC)-11 antibodies are used. Sections are stained with respective FITC
or rhodamine conjugated secondary antibodies and counterstained with DAPI for nuclear visualization.
Slides are analyzed using confocal microscopy.
[00230] Whether newly formed vessels are functional, and whether the vessels survive long term (or whether the vessels have atrophied or been eliminated due to apoptosis) are examined. Immunostaining is performed and the size and number of vessels is determined.
To distinguish the extent of cell survival versus apoptotic cell death at long term time points, newly formed coronary arteries are identified using a combination of RFP
staining, cell specific staining, and TUNEL and caspase-3/Bax antibody. Sections are stained with respective FITC or rhodamine conjugated secondary antibodies and counterstained with DAPI (151.ig/mL for nuclear visualization. Slides are analyzed using Olympus fluorescence and confocal microscopy. Furthermore, animals are treated with rhodamine-labeled dextran to determine whether newly generated coronary vessels are functional and have blood circulation. (Fatma et al., 2010; Singla et al., 2006; Singla et al., 2008;
Singla et al., 2011 (Mol. Pharm); Singla et al., 2011 (Am. J. Physiol. Heart Cir. Physiol.).
(5) DETERMINATION OF REGIONAL BLOOD FLOW FOLLOWING MI
To distinguish the extent of cell survival versus apoptotic cell death at long term time points, newly formed coronary arteries are identified using a combination of RFP
staining, cell specific staining, and TUNEL and caspase-3/Bax antibody. Sections are stained with respective FITC or rhodamine conjugated secondary antibodies and counterstained with DAPI (151.ig/mL for nuclear visualization. Slides are analyzed using Olympus fluorescence and confocal microscopy. Furthermore, animals are treated with rhodamine-labeled dextran to determine whether newly generated coronary vessels are functional and have blood circulation. (Fatma et al., 2010; Singla et al., 2006; Singla et al., 2008;
Singla et al., 2011 (Mol. Pharm); Singla et al., 2011 (Am. J. Physiol. Heart Cir. Physiol.).
(5) DETERMINATION OF REGIONAL BLOOD FLOW FOLLOWING MI
[00231] To determine if transplanted stem cells give rise to increased blood flow through new vessel formation, the commonly used non-radioactive isotope-labeled microspheres procedure is performed as described in Tillmans et al., 2008).
(6) FUNCTIONAL ASSESSMENT OF THE REGENERATED HEART
(6) FUNCTIONAL ASSESSMENT OF THE REGENERATED HEART
[00232] Echocardiography is an accurate noninvasive tool for the determination of quantitative characterization of heart remodeling following MI (Singla et al., 2008; Singla et al., 2011 (Am. J. Physiol. Heart Circ. Physiol.). Echocardiography is performed on infarcted hearts at short term post-MI time points (72 hrs and 14 days) and at long-term post-MI time points (3, 6, 12, and 16 weeks). M-mode images in a short axis view are performed to measure LV mass, LV mass to body ratio, LV anterior and posterior wall thickness, and fractional shortening.
3. DETERMINATION OF WHETHER FGF-9-IPS-CM ENHANCES ENDOGENOUS
ACTIVATION OF C-KIT+ FLK-1-vE CPCs AND FLKevE-PCs FOLLOWING MI
3. DETERMINATION OF WHETHER FGF-9-IPS-CM ENHANCES ENDOGENOUS
ACTIVATION OF C-KIT+ FLK-1-vE CPCs AND FLKevE-PCs FOLLOWING MI
[00233] Factors released from Akt transfected mesenchymal stem cells inhibit cardiac myocyte apoptosis (Gnecchi et al., 2005; Gnecchi et al., 2006). Some studies indicate that MSCs following transplantation in the infarcted heart restores c-kit positive CSCs niches (Hare 2007) and inhibit apoptosis. CPCs proliferation and differentiation was also activated by intramyocardial injection of HGF and IGF-1 in the infarcted myocardium (Tillmanns et al., 2008; Urbanek et al., 2003). Factors released from ES cells are different than those factors released from adult stem cells and inhibit H9C2 cell apoptosis (Singla et al., 2007; Singla et al., 2008). Following transplantation of ES-CM in the infarcted heart, cardiac myocyte apoptosis was significantly inhibited and function was improved. (Fatma et al., 2010; Singla et al., 2011 (Am J Physiol Heart Circ Physiol). Following transplantation of ES-CM in the infarcted heart, there was enhanced activation of CPCs and FLK-1+ve-PCs.
(Fatma et al., 2010; Singla et al., 2011). The enhanced activation contributed to cardiac neovascular regeneration via improved cardiac function. Moreover, following the intramyocardial injection of FGF-9 in the infarcted heart, there was enhanced neovascularization mediated via c-kit positive cells.
(I) DETERMINATION OF THE EFFECTS OF FACTORS RELEASED FROM IPS
CELLS ON C-KIT+vE CPCs AND FLK-1+vE-PC FOLLOWING MYOCARDIAL
INFARCTION
(Fatma et al., 2010; Singla et al., 2011). The enhanced activation contributed to cardiac neovascular regeneration via improved cardiac function. Moreover, following the intramyocardial injection of FGF-9 in the infarcted heart, there was enhanced neovascularization mediated via c-kit positive cells.
(I) DETERMINATION OF THE EFFECTS OF FACTORS RELEASED FROM IPS
CELLS ON C-KIT+vE CPCs AND FLK-1+vE-PC FOLLOWING MYOCARDIAL
INFARCTION
[00234] Using a cell culture model system (Fatma et al., 2010; Singla et al., 2007;
Singla et al., 2008; Singla et al., 2011), iPS-CM is produced from iPS-cells primed with and without FGF-9. Preparation of CM is well reported by us. A mouse myocardial infarction (MI) model (Fatma et al., 2010; Singla et al., 2007; Singla et al., 2008;
Singla et al., 2011) is used as well as C57BL/6 and db/db mice with and without cyclosporine A to inject FGF-9-iPS-CM (15x (Fatma et al., 2010; Singla et al., 2011), FGF-9 (1 ng/20 uL in two injections (50 ng/mL) or cell culture medium (as a control) using two intramyocardial injections following MI. Moreover, additional cell specific CM such ES-CM and H9c2-CM are used for comparison purposes. The effects on cardiac neovascularization are quantified.
Animals are killed humanely at short time points (72 hrs and 14 days) and long-term time points (3, 6, 12 and 16 weeks) following MI treatment for histological, physiological analysis, and preparation of tissue homogenates. To analyze the effect of iPS ¨CM, heart sections are prepared for immunostaining to determine CPCs and FLK-1-PCs niches and cell proliferation and differentiation. Echocardiography is used to examine heart function (2) IDENTIFICATION OF C-KIT-EvE CPC S AND FLK-evE-PCs AND THEIR
PROLIFERATION AND CELL DIVISION
Singla et al., 2008; Singla et al., 2011), iPS-CM is produced from iPS-cells primed with and without FGF-9. Preparation of CM is well reported by us. A mouse myocardial infarction (MI) model (Fatma et al., 2010; Singla et al., 2007; Singla et al., 2008;
Singla et al., 2011) is used as well as C57BL/6 and db/db mice with and without cyclosporine A to inject FGF-9-iPS-CM (15x (Fatma et al., 2010; Singla et al., 2011), FGF-9 (1 ng/20 uL in two injections (50 ng/mL) or cell culture medium (as a control) using two intramyocardial injections following MI. Moreover, additional cell specific CM such ES-CM and H9c2-CM are used for comparison purposes. The effects on cardiac neovascularization are quantified.
Animals are killed humanely at short time points (72 hrs and 14 days) and long-term time points (3, 6, 12 and 16 weeks) following MI treatment for histological, physiological analysis, and preparation of tissue homogenates. To analyze the effect of iPS ¨CM, heart sections are prepared for immunostaining to determine CPCs and FLK-1-PCs niches and cell proliferation and differentiation. Echocardiography is used to examine heart function (2) IDENTIFICATION OF C-KIT-EvE CPC S AND FLK-evE-PCs AND THEIR
PROLIFERATION AND CELL DIVISION
[00235] Following transplantation in the infarcted heart, resident CPCs have been identified and the role of these CPCs in neovascular regeneration has been determined. CPCs are lineage negative and are identified with cell specific markers. CPCs specific antibodies such as c-kit, MDR1 and sca-1 (Molecular Probes) are used to identify CPCs. To distinguish whether CPCs are migrated from the bone marrow, sections are stained for markers of hematopoietic cell lineage (such as CD34, Cd8, and CD45 (Molecular Probes, Santa Cruz)).
FLK-1 specific antibodies such as CD34 and FLK-1NEGF-R2 (Santa Cruz) are used to identify FLK-1 cells. The number of CPCs and FLK-1-PCs that have started proliferation and differentiation is determined.
(3) IDENTIFICATION OF PROGENITOR NEOVASCULAR CELL TYPES LINEAGE
FLK-1 specific antibodies such as CD34 and FLK-1NEGF-R2 (Santa Cruz) are used to identify FLK-1 cells. The number of CPCs and FLK-1-PCs that have started proliferation and differentiation is determined.
(3) IDENTIFICATION OF PROGENITOR NEOVASCULAR CELL TYPES LINEAGE
[00236] Using double-label immunostaining to detect CPCs (c-kit, MDR1 and sca-1 antibody) and using cell specific antibodies to detect neovascular specific progenitor cell types such as VSMCs and ECs using (Fatma et al., 2010), cell specific lineage progenitor cells are determined. To determine progenitor ECs, sections are immunostained with endothelial specific transcription factors Ets-1, Fli-1, Etv2, and Erg 1 (Sigma, Molecular Probes) and structural protein flkl (Santa Cruz) antibodies. For progenitor smooth muscle cells, transcription factors GATA 6 and GATA 2 and structural protein a-SM
actin antibodies (Sigma) are used. Sections will then be stained with respective FITC or rhodamine conjugated secondary antibodies and counterstained with DAPI for nuclear visualization.
Slides are analyzed using Olympus fluorescence and confocal microscopy. The number of CPCs in the acute and chronic cardiomyopathy is quantified. RT-PCR and western blot is performed to confirm increased levels of endothelial and vascular smooth muscle cells transcriptional factors and protein levels.
4. DETERMINATION OF WHETHER TRANSPLANTED FGF-9 PRIMED IPS CELLS OR
PATHWAY
actin antibodies (Sigma) are used. Sections will then be stained with respective FITC or rhodamine conjugated secondary antibodies and counterstained with DAPI for nuclear visualization.
Slides are analyzed using Olympus fluorescence and confocal microscopy. The number of CPCs in the acute and chronic cardiomyopathy is quantified. RT-PCR and western blot is performed to confirm increased levels of endothelial and vascular smooth muscle cells transcriptional factors and protein levels.
4. DETERMINATION OF WHETHER TRANSPLANTED FGF-9 PRIMED IPS CELLS OR
PATHWAY
[00237] miRNAs are small non-coding RNAs about 20-24 nucleotides in length that play a major role in the regulation of a variety of cell processes including apoptosis, hypertrophy, fibrosis, and cardiac differentiation (Care et al., 2007;
Catalucci et al., 2008;
Chen et al., 2006; Cimmino et al., 2005). The deletion of miR-126 was reported to demonstrate loss in vascular integrity and defects in ECs proliferation in the mice with and without myocardial infarction (Wang et al., 2008). Furthermore, miR-126 inhibited SPRED1 and PIK3R2, which are both negative regulators of the VEGF signaling pathway (Wang et al., 2008; Heusschen et al., 2010).
Catalucci et al., 2008;
Chen et al., 2006; Cimmino et al., 2005). The deletion of miR-126 was reported to demonstrate loss in vascular integrity and defects in ECs proliferation in the mice with and without myocardial infarction (Wang et al., 2008). Furthermore, miR-126 inhibited SPRED1 and PIK3R2, which are both negative regulators of the VEGF signaling pathway (Wang et al., 2008; Heusschen et al., 2010).
[00238] These studies determine the role of the miR-126 pathway in neovascularization in diabetic infarcted mouse hearts as well as determine the effect of transplanted FGF-9 primed iPS cells or FGF-9-iPS-CM. The presence of decreased neovascularization that leads to decreased cardiac function in the infarcted mouse heart was demonstrated. Next, transplanted iPS cells enhanced neovascularization with improved cardiac function. Moreover, the levels of miR-126 were significantly reduced following MI
and this decrease was reversed with cell transplantation.
(1) DETERMINATION OF THE EFFECTS OF FGF-9-IPS CELLS OR IPS-CM ON
and this decrease was reversed with cell transplantation.
(1) DETERMINATION OF THE EFFECTS OF FGF-9-IPS CELLS OR IPS-CM ON
[00239] Using RT-PCR, the levels of miR-126 following MI are determined (Glass et al., 2011) and miR-126 levels are confirmed with northern blotting (Dey et al, 2011;
Narducci et al., 2011; Small et al., 2010). To determine the role of miR-126 on neovascularization, animals are injected with a selective inhibitor of miR-126 (locked nucleic acid, LNA-antagomir-126, 80mg/kg, as this dose is used by other investigators (Hartley et al., 2010; Patrick et al., 2010). To identify expression of miR-126 in the infarcted, non-infarcted, and peri-infarcted region of the heart following MI, heart sections are stained using in situ-hybridization for miR-126. In situ-hybridization employing LNA-miR-126 specific probes (Exiqon) (Hosada et al., 2011) is utilized. Additionally, expression of miR-126 in major heart cell types is characterized using double label immunostaining with cell specific antibodies. In brief, after in situ hybridization, sections are co-labeled with neovascular cell specific antibodies such as CD31 for endothelial cells and smooth muscle a-actin for VSM cells.
Sections are counter stained with DAPI to identify cell nuclei.
Narducci et al., 2011; Small et al., 2010). To determine the role of miR-126 on neovascularization, animals are injected with a selective inhibitor of miR-126 (locked nucleic acid, LNA-antagomir-126, 80mg/kg, as this dose is used by other investigators (Hartley et al., 2010; Patrick et al., 2010). To identify expression of miR-126 in the infarcted, non-infarcted, and peri-infarcted region of the heart following MI, heart sections are stained using in situ-hybridization for miR-126. In situ-hybridization employing LNA-miR-126 specific probes (Exiqon) (Hosada et al., 2011) is utilized. Additionally, expression of miR-126 in major heart cell types is characterized using double label immunostaining with cell specific antibodies. In brief, after in situ hybridization, sections are co-labeled with neovascular cell specific antibodies such as CD31 for endothelial cells and smooth muscle a-actin for VSM cells.
Sections are counter stained with DAPI to identify cell nuclei.
[00240] To determine the effects of miR-126 on downstream targeted protein SPREAD1 and PIK3R2, SDS-PAGE and Western blot analyses are performed to determine the protein expression of total and phosphorylated SPRED1 and PIK3R2 (Abcam, USA).
Densitometry is used to measure band density.
Densitometry is used to measure band density.
[00241] All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention.
[00242] More specifically, certain agents which are both chemically and physiologically related can be substituted for the agents described herein while the same or similar results can be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
[00243] Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
E. REFERENCES
E. REFERENCES
[00244] The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
[00245] Abel,E.D. Myocardial insulin resistance and cardiac complications of diabetes.
Curr. Drug Targets. Immune. Endocr. Metabol. Disord. 5, 219-226 (2005).
Curr. Drug Targets. Immune. Endocr. Metabol. Disord. 5, 219-226 (2005).
[00246] Amos,A.F., et al. The rising global burden of diabetes and its complications:
estimates and projections to the year 2010. Diabet. Med. 14 Suppl 5, S1-85 (1997).
estimates and projections to the year 2010. Diabet. Med. 14 Suppl 5, S1-85 (1997).
[00247] Behfar,A. et al. Stem cell differentiation requires a paracrine pathway in the heart. FASEB J. 16, 1558-1566 (2002).
[00248] Behr,B., et al. Fgf-9 is required for angiogenesis and osteogenesis in long bone repair. Proc. Natl. Acad. Sci. U. S. A 107, 11853-11858 (2010).
[00249] Beltrami,A.P. et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114, 763-776 (2003).
[00250] Biesecker,L.G. et al. Interleukin-6 is a component of human umbilical cord serum and stimulates hematopoiesis in embryonic stem cells in vitro. Exp.
Hematol. 21, 774-778 (1993).
Hematol. 21, 774-778 (1993).
[00251] Care,A. et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med.
13, 613-618 (2007).
13, 613-618 (2007).
[00252] Catalucci,D., Latronico,M.V., & Condorelli,G. MicroRNAs control gene expression: importance for cardiac development and pathophysiology Ann. N. Y.
Acad. Sci.
1123, 20-29 (2008).
Acad. Sci.
1123, 20-29 (2008).
[00253] Chang,M.Y. et al. Direct reprogramming of rat neural precursor cells and fibroblasts into pluripotent stem cells. PLoS. One. 5, e9838 (2010).
[00254] Chen,J.F. et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38, 228-233 (2006).
[00255] Cimmino,A. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2.
Proc. Natl. Acad. Sci. U. S. A 102, 13944-13949 (2005).
Proc. Natl. Acad. Sci. U. S. A 102, 13944-13949 (2005).
[00256] Damjanov,I. From stem cells to germ cell tumors and back. Verh.
Dtsch. Ges.
Pathol. 88, 39-44 (2004).
Dtsch. Ges.
Pathol. 88, 39-44 (2004).
[00257] Dey,B.K., et al. miR-206 and -486 induce myoblast differentiation by downregulating Pax7. Mol. Cell Biol. 31, 203-214 (2011).
[00258] Dyer,L.A. et al. The role of secondary heart field in cardiac development. Dev.
Biol. 336, 137-144 (2009).
Biol. 336, 137-144 (2009).
[00259] Fatma,S., et al. Factors Released from Embryonic Stem Cells Stimulate c-kit-FLK-1(+ve) Progenitor Cells and Enhance Neovascularization. Antioxid. Redox.
Signal. 13, 1857-1865 (2010).
Signal. 13, 1857-1865 (2010).
[00260] Frontini,M.J. et al. Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells.
Nat.
Biotechnol. 29, 421-427 (2011).
Nat.
Biotechnol. 29, 421-427 (2011).
[00261] Giralt,S. et al. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J. Clin. Oncol. 15, 667-673 (1997).
[00262] Glass,C.E., et al. Stem cells in the diabetic infarcted heart.
Heart Fail.
Rev.(2010).
Heart Fail.
Rev.(2010).
[00263] Gnecchi,M. et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement.
FASEB J.
20, 661-669 (2006).
FASEB J.
20, 661-669 (2006).
[00264] Gnecchi,M. et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat. Med. 11, 367-368 (2005).
[00265] Hatley,M.E. et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 18, 282-293 (2010).
[00266] Heusschen,R., et al. MicroRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard. Biochim. Biophys. Acta 1805, 87-96 (2010).
[00267] Hosoda,T. et al. Human cardiac stem cell differentiation is regulated by a mircrine mechanism. Circulation 123, 1287-1296 (2011).
[00268] Jujo,K., et al. Endothelial progenitor cells in neovascularization of infarcted myocardium. J. Mol. Cell Cardiol. 45, 530-544 (2008).
[00269] Kim,K. et al. Epigenetic memory in induced pluripotent stem cells.
Nature 467, 285-290 (2010).
Nature 467, 285-290 (2010).
[00270] Kobayashi,M. et al. Expression of Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 in pancreatic beta-Cells and its role in promotion of insulin secretion and protection against diabetes. Endocrinology 149, 5662-5669 (2008).
[00271] Kofidis,T. et al. Stimulation of paracrine pathways with growth factors enhances embryonic stem cell engraftment and host-specific differentiation in the heart after ischemic myocardial injury. Circulation 111, 2486-2493 (2005).
[00272] Korf-Klingebiel,M. et al. Conditional transgenic expression of fibroblast growth factor 9 in the adult mouse heart reduces heart failure mortality after myocardial infarction. Circulation 123, 504-514 (2011).
[00273] Krenning,G., et al. Generating new blood flow: integrating developmental biology and tissue engineering. Trends Cardiovasc. Med. 18, 312-323 (2008).
[00274] Kuzmenkin,A. et al. Functional characterization of cardiomyocytes derived from murine induced pluripotent stem cells in vitro. FASEB J. 23, 4168-4180 (2009).
[00275] Lunde,K. et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med. 355, 1199-1209 (2006).
[00276] Marques,S.R., et al. Reiterative roles for FGF signaling in the establishment of size and proportion of the zebrafish heart. Dev. Biol. 321, 397-406 (2008).
[00277] Menard,C. et al. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet 366, 1005-1012 (2005).
[00278] Narducci,M.G. et al. MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death. Dis.
2, el51 (2011).
2, el51 (2011).
[00279] Nelson,T.J. et al. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation 120, 408-416 (2009).
[00280] Nussbaum,J. et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J. 21, 1345-1357 (2007).
[00281] Park,I.H. et al. Disease-specific induced pluripotent stem cells.
Cell 134, 877-886 (2008).
Cell 134, 877-886 (2008).
[00282] Park,I.H., et al. Generation of human-induced pluripotent stem cells. Nat.
Protoc. 3, 1180-1186 (2008).
Protoc. 3, 1180-1186 (2008).
[00283] Patrick,D.M. et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Invest 120, 3912-3916 (2010).
[00284] Singla,D.K., et al. Factors released from embryonic stem cells inhibit apoptosis of H9c2 cells. Am. J. Physiol Heart Circ. Physiol 293, H1590-H1595 (2007).
[00285] Singla,D.K., et al. Enhancement by growth factors of cardiac myocyte differentiation from embryonic stem cells: A promising foundation for cardiac regeneration.
Biochem. Biophys. Res. Commun. 335, 637-642 (2005).
Biochem. Biophys. Res. Commun. 335, 637-642 (2005).
[00286] Singla,D.K. Embryonic stem cells in cardiac repair and regeneration.
Antioxid. Redox. Signal. 11, 1857-1863 (2009).
Antioxid. Redox. Signal. 11, 1857-1863 (2009).
[00287] Singla,D.K. et al. Transplantation of embryonic stem cells into the infarcted mouse heart: formation of multiple cell types. J. Mol. Cell Cardiol. 40, 195-200 (2006).
[00288] Singla,D.K. Stem cells in the infarcted heart. J. Cardiovasc.
Transl. Res. 3, 73-78 (2010).
Transl. Res. 3, 73-78 (2010).
[00289] Singla,D.K., et al. iPS Cells Repair and Regenerate Infarcted Myocardium.
Mol. Pharm.(2011).
Mol. Pharm.(2011).
[00290] Singla,D.K., et al Transplanted embryonic stem cells following mouse myocardial infarction inhibit apoptosis and cardiac remodeling. Am. J. Physiol Heart Circ.
Physiol 293, H1308-H1314 (2007).
Physiol 293, H1308-H1314 (2007).
[00291] Singla,D.K., et al. Factors released from embryonic stem cells inhibit apoptosis in H9c2 cells through PI3K/Akt but not ERK pathway. Am. J. Physiol Heart Circ.
Physiol 295, H907-H913 (2008).
Physiol 295, H907-H913 (2008).
[00292] Singla,D.K., et alet al TGF-beta2 treatment enhances cytoprotective factors released from embryonic stem cells and inhibits apoptosis in infarcted myocardium. Am. J.
Physiol Heart Circ. Physiol 300, H1442-H1450 (2011).
Physiol Heart Circ. Physiol 300, H1442-H1450 (2011).
[00293] Slager,H.G., et al. Transforming growth factor-beta in the early mouse embryo: implications for the regulation of muscle formation and implantation.
Dev. Genet.
14, 212-224 (1993).
Dev. Genet.
14, 212-224 (1993).
[00294] Small,E.M. et al. Regulation of P13-kinase/Akt signaling by muscle-enriched microRNA-486. Proc. Natl. Acad. Sci. U. S. A 107, 4218-4223 (2010).
[00295] Takahashi,K., et al. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006).
[00296] Tendera,M. et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial Eur. Heart J. 30, 1313-1321 (2009).
[00297] Thomson,J.A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 (1998).
[00298] Tillmanns,J. et al. Formation of large coronary arteries by cardiac progenitor cells. Proc. Natl. Acad. Sci. U. S. A 105, 1668-1673 (2008).
[00299] Urbanek,K. et al. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A 100, 10440-10445 (2003).
[00300] Urbanek,K. et al. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc. Natl. Acad. Sci. U. S. A 102, 8692-8697 (2005).
[00301] Wang,S. et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15, 261-271 (2008).
[00302] White,A.C., et al. FGF-9 and SHH regulate mesenchymal Vegfa expression and development of the pulmonary capillary network. Development 134, 3743-3752 (2007).
[00303] Wiles,M.V., et al. Multiple hematopoietic lineages develop from embryonic stem (ES) cells in culture. Development 111, 259-267 (1991).
[00304] Yun,Y.R. et al. Fibroblast growth factors: biology, function, and application for tissue regeneration. J. Tissue Eng 2010, 218142 (2010).
[00305] Zhang,J. et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ. Res. 104, e30-e41 (2009).
[00306] Zhao,T., et al. Immunogenicity of induced pluripotent stem cells.
Nature (2011).
Nature (2011).
Claims (88)
1. A method of enhancing neovascularization following cardiac dysfunction in a subject in need thereof, the method comprising:
(i) administering to the subject fibroblast growth factor-9 primed induced pluripotent stem cells;
(ii) administering to the subject conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells;
(iii) administering to the subject fibroblast growth factor-9; and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8; and and determining neovascularization in the heart.
(i) administering to the subject fibroblast growth factor-9 primed induced pluripotent stem cells;
(ii) administering to the subject conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells;
(iii) administering to the subject fibroblast growth factor-9; and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8; and and determining neovascularization in the heart.
2. A method of attenuating vascular apoptosis and/or apoptosis-related mechanisms following cardiac dysfunction in a subject in need thereof comprising:
(i) administering to the subject fibroblast growth factor-9 primed induced pluripotent stem cells;
(ii) administering to the subject conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells;
(iii) administering to the subject fibroblast growth factor-9; and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8; and and determining apoptosis and/or apoptosis related mechanisms in the heart.
(i) administering to the subject fibroblast growth factor-9 primed induced pluripotent stem cells;
(ii) administering to the subject conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells;
(iii) administering to the subject fibroblast growth factor-9; and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8; and and determining apoptosis and/or apoptosis related mechanisms in the heart.
3. The method of claim 1 or claim 2, wherein the subject is diabetic.
4. The method of claim 1, wherein enhancing neovascularization comprises enhancing cell engraftment.
5. The method of claim 1, wherein enhancing neovascularization comprises enhancing cell proliferation.
6. The method of claim 1, wherein enhancing neovascularization comprises enhancing cell differentiation.
7. The method of claim 1 or claim 2, wherein the induced pluripotent stem cells differentiate into endothelial cells and/or vascular smooth muscles cells.
8. The method of claim 1 or claim 2, further comprising enhancing angiogenesis and/or vasculogenesis in the subject.
9. The method of claim 1 or claim 2, further comprising enhancing cardiac function in the subject.
10. The method of claim 9, wherein enhancing cardiac function comprises increasing cardiac blood flow.
11. The method of claim 9, wherein enhancing cardiac function comprises increasing cardiac capillary density.
12. The method of claim 1 or claim 2, wherein the conditioned media comprises anti-apoptotic and anti-fibrotic factors.
13. The method of claim 12, wherein anti-apoptotic factors and anti-fibrotic comprise fibroblast growth factor-8, fibroblast growth factor-9, interleukin-10, and tissue inhibitor of matrix metalloproteinase-1.
14. The method of claim 1, further comprising attenuating vascular apoptosis and/or apoptosis-related mechanisms.
15. The method of claim 2 or claim 14, wherein apoptosis and/or apoptosis-related mechanisms occurs in the induced pluripotent stem cells.
16. The method of claim 2 or claim 14, wherein apoptosis and/or apoptosis-related mechanisms occurs in cardiac tissue of the subject.
17. The method of claim 2 or claim 14, wherein miR-126 expression increases, expression decreases, PIK3R2 expression decreases, and/or a combination thereof
18. The method of claim 1 or claim 2, wherein the induced pluripotent stem cells are cardiac-committed.
19. The method of claim 1 or claim 2, wherein between 5,000 and 500,000 induced pluripotent stem cells are administered to the subject.
20. The method of claim 19, wherein approximately 100,000 induced pluripotent stem cells are administered to the subject.
21. The method of claim 19, wherein less than 100,000 induced pluripotent stem cells are administered to the subject.
22. The method of claim 19, wherein more than 100,000 induced pluripotent stem cells are administered to the subject.
23. The method of any one of claims 19-22, wherein the induced pluripotent stem cells are administered in one intramyocardial injection.
24. The method of any one of claims 19-22, wherein the induced pluripotent stem cells are administered in two or more intramyocardial injections.
25. The method of any one of claims 19-22, wherein the induced pluripotent stem cells are administered into a peri-infarct zone and/or an infarcted zone of the injured myocardium.
26. The method of claim 1 or claim 2, further comprising administering to the subject one or more immunosuppressive drugs.
27. The method of claim 26, wherein the one or more immunosuppressive drugs comprise corticosteroids, calcineurin inhibitors, anti-proliferatives, and mTOR
inhibitors.
inhibitors.
28. The method of claim 26, wherein the one or more immunosuppressive drugs is cyclosporine A.
29. The method of claim 26, wherein the one or more immunosuppressive drugs is administered to the subject prior to, during, and/or following the administration of the induced pluripotent stem cells.
30. The method of claim 1 or claim 2, further comprising administering fibroblast growth factor-9 to the subject.
31. The method of claim 30, wherein the fibroblast growth factor-9 is administered to the subject prior to, during, and/or following the administration of the induced pluripotent stem cells.
32. The method of claim 1 or claim 2, further comprising repeating the administration of induced pluripotent stem cells to the subject.
33. The method of claim 32, further comprising repeating the administration of fibroblast growth factor-9 to the subject.
34. The method of claim 1 or claim 2, wherein the cardiac dysfunction is a cardiac ischemia/reperfusion event.
35. The method of claim 34, wherein the ischemia/reperfusion event is myocardial infarction, myocardial ischemia, myocardial reperfusion, subendocardial ischemia, Takayasu's arteritis, atrial fibrillation, hemorrhagic stroke, an event that occurs during cardiac surgery where a heart lung machine is used such as coronary artery bypass, or an event that occurs during the preservation of an organ for transplant.
36. The method of claim 1 or claim 2, wherein the cardiac dysfunction is a congenital heart defect.
37. The method of claim 36, wherein the congenital heart defect is hypoplasia or pentalogy of Cantrell.
38. The method of claim 1 or claim 2, wherein the induced pluripotent stem cells are administered to the subject prior to, during, and/or following cardiac dysfunction.
39. The method of claim 38, wherein the induced pluripotent stem cells are administered within 10, 15, 20, 25, 30, or more minutes following cardiac dysfunction.
40. The method of claim 38, wherein the induced pluripotent stem cells are administered within 1, 2, 6, 12, 18, 24, or more hours following cardiac dysfunction.
41. The method of claim 1 or claim 2, wherein the induced pluripotent stem cells are obtained from an autologous, allogeneic, or syngeneic source.
42. The method of claim 1 or claim 2, wherein the induced pluripotent stem cells are obtained from fibroblast cells.
43. The method of claim 1 or claim 2, wherein the induced pluripotent stem cells are obtained from H9c2 cells.
44. The method of claim 42 or claim 43, wherein the fibroblast cells or the H9c2 cells transfected with a vector comprising a nucleic acid molecule encoding at least one stemness factor.
45. The method of claim 44, wherein the at least one stemness factor comprises c-myc, oct 3/4, Klf4, nanog, Sox2, and/or a combination thereof.
46. A composition for enhancing neovascularization in a subject, the composition comprising (i) fibroblast growth factor-9 primed induced pluripotent stem cells; (ii) conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells;
(iii) administering to the subject fibroblast growth factor-9; and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
(iii) administering to the subject fibroblast growth factor-9; and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
47. A composition for attenuating vascular apoptosis and/or apoptosis-related mechanisms in a subject, the composition comprising (i) fibroblast growth factor-9 primed induced pluripotent stem cells; (ii) conditioned medium of fibroblast growth factor-9 primed induced pluripotent stem cells; (iii) administering to the subject fibroblast growth factor-9; and/or (iv) administering to the subject a composition comprising fibroblast growth factor-9 and fibroblast growth factor-8.
48. The composition of claim 46 or claim 47, wherein the subject is diabetic.
49. The composition of claim 46 or claim 47, wherein the subject has experienced a cardiac ischemia/reperfusion event.
50. The composition of claim 49, wherein the ischemia/reperfusion event is myocardial infarction, myocardial ischemia, myocardial reperfusion, subendocardial ischemia, Takayasu's arteritis, atrial fibrillation, hemorrhagic stroke, an event that occurs during cardiac surgery where a heart lung machine is used such as coronary artery bypass, or an event that occurs during the preservation of an organ for transplant.
51. The composition of claim 46 or claim 47, wherein the subject has a congenital heart defect.
52. The composition of claim 51, wherein the congenital heart defect is hypoplasia or pentalogy of Cantrell.
53. The composition of claim 46 or claim 47, wherein the composition is administered within 10, 15, 20, 25, 30, or more minutes following the ischemia/reperfusion event.
54. The composition of claim 46 or claim 47, wherein the composition is administered within 1, 2, 6, 12, 18, 24, or more hour following the ischemia/reperfusion event.
55. The composition of claim 46, wherein the composition enhances cell engraftment.
56. The composition of claim 46, wherein the composition enhances cell proliferation.
57. The composition of claim 46, wherein the composition enhances cell differentiation.
58. The composition of claim 46 or claim 47, wherein the induced pluripotent stem cells differentiate into endothelial cells and/or vascular smooth muscle cells.
59. The composition of claim 46 or claim 47, wherein the composition enhances angiogenesis and/or vasculogenesis in the subject.
60. The composition of claim 46 or claim 47, wherein the composition enhances cardiac function in the subject.
61. The composition of claim 60, wherein enhancing cardiac function comprises increases cardiac blood flow.
62. The composition of claim 60, wherein enhancing cardiac function comprises increases cardiac capillary density.
63. The composition of claim 46 or claim 47, wherein the conditioned media comprises anti-apoptotic and anti-fibrotic factors.
64. The composition of claim 63, wherein anti-apoptotic factors and anti-fibrotic comprise fibroblast growth factor-8, fibroblast growth factor-9, interleukin-10, and tissue inhibitor of matrix metalloproteinase-1.
65. The composition of claim 46, wherein the composition attenuates vascular apoptosis and/or apoptosis-related mechanisms.
66. The composition of claim 47 or claim 65, wherein the composition attenuates apoptosis and/or apoptosis-related mechanisms of the induced pluripotent stem cells.
67. The composition of claim 47 or claim 65, wherein the composition attenuates apoptosis and/or apoptosis-related mechanisms in cardiac tissue of the subject.
68. The composition of claim 47 or claim 65, wherein the composition increases miR-126 expression, decreases SPRED1 expression, decreases PIK3R2 expression, and/or a combination thereof.
69. The composition of claim 46 or claim 47, wherein the induced pluripotent stem cells are cardiac-committed.
70. The composition of claim 46 or claim 47, wherein the composition comprises 5,000 and 500,000 induced pluripotent stem cells.
71. The composition of claim 70, wherein the composition comprises approximately 100,000 induced pluripotent stem cells.
72. The composition of claim 70, wherein the composition comprises less than 100,000 induced pluripotent stem cells.
73. The composition of claim 70, wherein the composition comprises more than 100,000 induced pluripotent stem cells.
74. The composition of any one of claims 70-73, wherein the composition is administered to the subject in one intramyocardial injection.
75. The composition of any one of claims 70-73, wherein the composition is administered to the subject in two or more intramyocardial injections.
76. The composition of any one of claims 70-73, wherein the composition is administered into a peri-infarct zone and/or into an infarcted zone of the injured myocardium.
77. The composition of claim 46 or claim 47, further comprising one or more immunosuppressive drugs.
78. The composition of claim 77, wherein the one or more immunosuppressive drugs comprise corticosteroids, calcineurin inhibitors, anti-proliferatives, and mTOR
inhibitors.
inhibitors.
79. The composition of claim 77, wherein the one or more immunosuppressive drug is cyclosporine A.
80. The composition of claim 46 or claim 47, further comprising fibroblast growth factor-9.
81. The composition of claim 46 or claim 47, wherein the induced pluripotent stem cells are obtained from an autologous, allogeneic, or syngeneic source.
82. The composition of claim 46 or claim 47, wherein the induced pluripotent stem cells are obtained from fibroblast cells.
83. The composition of claim 46 or claim 47, wherein the induced pluripotent stem cells are obtained from H9c2 cells.
84. The composition of claim 46 or claim 47, wherein the fibroblast cells or the H9c2 cells transfected with a vector comprising a nucleic acid molecule encoding at least one stemness factor.
85. The composition of claim 84, wherein the at least one stemness factor comprises c-myc, oct 3/4, Klf4, nanog, Sox2, and/or a combination thereof.
86. A method of generating cardiac induced pluripotent stem cells, the method comprising:
(i) inserting one or more nucleic acid constructs capable of expressing stem-cell like factors into a cardiac cell type, wherein the stem-cell like factors comprise Oct3/4, KIf4, Sox2, c-Myc, and/or a combination thereof and (ii) obtaining the cardiac induced pluripotent stem cells stably expressing the stem-cell like factors in the cardiac cell type.
(i) inserting one or more nucleic acid constructs capable of expressing stem-cell like factors into a cardiac cell type, wherein the stem-cell like factors comprise Oct3/4, KIf4, Sox2, c-Myc, and/or a combination thereof and (ii) obtaining the cardiac induced pluripotent stem cells stably expressing the stem-cell like factors in the cardiac cell type.
87. A method of inhibiting vascular apoptosis and/or apoptosis-related mechanisms, comprising: administering conditioned medium from induced pluripotent stem cells, wherein the conditioned medium is administered with or without fibroblast growth factor-9.
88. A method of inhibiting vascular apoptosis, comprising: administering fibroblast growth factor-9.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618280P | 2012-03-30 | 2012-03-30 | |
| US61/618,280 | 2012-03-30 | ||
| PCT/US2013/030082 WO2013148122A1 (en) | 2012-03-30 | 2013-03-09 | Methods and compositions using fgf-9 to enchance neovascularization and regeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2869169A1 true CA2869169A1 (en) | 2013-10-03 |
Family
ID=49261002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2869169A Abandoned CA2869169A1 (en) | 2012-03-30 | 2013-03-09 | Methods and compositions using fgf-9 to enhance neovascularization and regeneration |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2830711A4 (en) |
| CA (1) | CA2869169A1 (en) |
| WO (1) | WO2013148122A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015164800A2 (en) * | 2014-04-24 | 2015-10-29 | University Of Central Florida Research Foundation, Inc. | Compositions and methods for modulating polarization of monocytes |
| CN104587103B (en) * | 2014-12-04 | 2018-10-19 | 南京中医药大学 | A kind of extracting method that treating hemorrhagic stroke traditional medicine volatile oil extract component group and its application |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7764995B2 (en) * | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
| CN101084007A (en) * | 2004-09-22 | 2007-12-05 | 金齐姆公司 | Use of tgf-beta antagonists to limit nephrotoxicity of immunosuppressive agents |
| US20070065415A1 (en) * | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
| CA2733556A1 (en) * | 2008-08-11 | 2010-02-18 | The Board Of Regents Of The University Of Texas System | A micro-rna that promotes vascular integrity and uses thereof |
| WO2010031190A1 (en) * | 2008-09-22 | 2010-03-25 | UNIVERSITé LAVAL | Culture medium for myoblasts, precursors thereof and derivatives thereof |
-
2013
- 2013-03-09 CA CA2869169A patent/CA2869169A1/en not_active Abandoned
- 2013-03-09 EP EP13770266.8A patent/EP2830711A4/en not_active Withdrawn
- 2013-03-09 WO PCT/US2013/030082 patent/WO2013148122A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2830711A4 (en) | 2015-08-26 |
| EP2830711A1 (en) | 2015-02-04 |
| WO2013148122A1 (en) | 2013-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Laflamme et al. | Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts | |
| TWI492707B (en) | Pharmaceutical composition for the treatment of heart diseases | |
| JP2024016026A (en) | Transient cellular reprogramming to reverse cellular aging | |
| CN102046193B (en) | Compositions and methods for treating cardiac tissue using cells | |
| US20210079351A1 (en) | Tissue-specific differentiation matrices and uses thereof | |
| US20110280834A1 (en) | Methods and compositions for cardiac tissue regeneration | |
| US20130078718A1 (en) | Conversion of vascular endothelial cells into multipotent stem-like cells | |
| Kandalam et al. | Human dental stem cells of the apical papilla associated to BDNF-loaded pharmacologically active microcarriers (PAMs) enhance locomotor function after spinal cord injury | |
| Van Laake et al. | Cardiomyocytes derived from stem cells | |
| Singla | Embryonic stem cells in cardiac repair and regeneration | |
| Nakamura et al. | Increased angiogenesis and improved left ventricular function after transplantation of myoblasts lacking the MyoD gene into infarcted myocardium | |
| EP3080246A2 (en) | Compositions and methods for producing and administering brown adipocytes | |
| CA2869169A1 (en) | Methods and compositions using fgf-9 to enhance neovascularization and regeneration | |
| Quinn et al. | In vivo differentiation potential of mesenchymal stem cells: prenatal and postnatal model systems | |
| US20150328285A1 (en) | Methods and compositions using fgf-9 to enhance neovascularization and regeneration | |
| de Lázaro et al. | Non-viral induction of transient cell reprogramming in skeletal muscle to enhance tissue regeneration | |
| Lin et al. | Adipose-derived stem cells: therapy through paracrine actions | |
| Domenig et al. | Stem cell-based and tissue engineering approaches for skeletal muscle repair | |
| US11963983B2 (en) | Methods of cardiac repair | |
| EP2830639B1 (en) | Methods and compositions using fgf-8 to enhance cardiac regeneration and attenuate adverse cardiac remodeling | |
| US20200190475A1 (en) | Methods for identifying and isolating cardiac stem cells and methods for making and using them | |
| Pesaresi | Exogenous expression of chemokine receptors improves mouse mesenchymal stem cell migration towards the degenerating retina | |
| Reis et al. | GDF11 and its receptor ALK4 independently modulate human myoblast migration and fusion | |
| Rao | Epicardial cell engraftment and signaling promote cardiac repair after myocardial infarction | |
| Seale et al. | Adult skeletal muscle growth and regeneration: The development and differentiation of myogenic stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20180309 |